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Abstract
Increasing evidence suggests that immune responses are involved in the control of cancer and that
the immune system can be manipulated in different ways to recognize and attack tumors. Progress
in immune-based strategies has opened new therapeutic avenues using a number of techniques
destined to eliminate malignant cells. In the present review, we overview current knowledge on the
importance, successes and difficulties of immunotherapy in liver tumors, including preclinical data
available in animal models and information from clinical trials carried out during the lasts years. This
review shows that new options for the treatment of advanced liver tumors are urgently needed
and that there is a ground for future advances in the field.
Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer and the third leading cause of cancer-related
death worldwide [1]. Unfortunately, the incidence and
mortality associated with HCC is increasing steadily [2] as
a consequence of epidemics of hepatitis C virus (HCV)
and hepatitis B virus (HBV). HCV and HBV infections are
causally associated with the majority of HCC in the world
[3].
Current therapeutic options are extremely disappointing
since less than 30% of the patients evaluated in referral
medical institutions can receive a curative therapy, con-
sisting in either resection or transplantation [4]. Thus, in
the majority of advanced HCC cases surgery is not possi-
ble and the prognosis is dismal due to underlying cirrho-
sis as well as to poor tumor response to chemotherapeutic
agents [4-6].
Unfortunately, advanced colorectal carcinoma (CRC)
depict similar scenario [7]. Colorectal carcinoma is one of
the most common malignancies and a leading cause of
cancer-related death [1]. Hepatic metastases are present in
15–25% of patients at the time of CRC diagnosis [8]. Sur-
gical resection, which is accepted as first-line
Published: 6 March 2009
Journal of Biomedical Science 2009, 16:30 doi:10.1186/1423-0127-16-30
Received: 28 October 2008
Accepted: 6 March 2009
This article is available from: http://www.jbiomedsci.com/content/16/1/30
© 2009 Matar et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 18
(page number not for citation purposes)
The cost of publication in Journal of Biomedical Science
is bourne by the National Science Council, Taiwan.
Journal of Biomedical Science 2009, 16:30 http://www.jbiomedsci.com/content/16/1/30CRC treatment, cannot be performed in the majority of
patients [9]. Following diagnosis, the median survival of
untreated patients with liver metastases is 6–12 months
[10]. The application of new chemotherapeutic cocktails,
including irinotecan or oxaliplatin, result in higher rates
of objective responses and survival [11-15] and the recent
incorporation of monoclonal antibodies against vascular
endothelial growth factor and epidermal growth factor
receptors provides additional, although limited, improve-
ment in patients survival [15,16].
Thus, new strategies are needed for treatment of patients
with advanced liver tumors and immunotherapy
approaches might play a significant role among them.
Cancer immunotherapy can be defined as a set of tech-
niques aimed to eliminate malignant tumors through
mechanisms involving immune system responses [17,18].
The goal of cancer immunotherapy is to understand how
to direct against tumors similar kind of extremely potent
immune responses such as those naturally occurring
against microbial antigens, and subsequently how to
apply these results to human cancer diseases. It has been
observed in patients with HCC that the presence of a lym-
phocyte infiltrate is associated with a better prognosis
after resection and transplantation [19]. Similarly, pres-
ence of lymphocyte infiltration in tumors was correlated
with patient survival in CRC: survival rate of patients with
large numbers of CD3+-T cells was 5-years higher [20,21].
There is a limited clinical experience regarding the appli-
cation of immunotherapy in liver tumors contrary to
more immunogenic tumors such as melanoma, lym-
phoma or renal cell carcinoma. Increasing evidence sug-
gests that immune responses are involved in the control of
cancer and that the immune system can be manipulated
in different ways to recognize and attack tumors (Fig. 1).
Unfortunately, the presence of chronic HCV or HBV infec-
tion complicates the success of immunotherapy in
patients with HCC because these viruses were found to be
able to modulate the immune response against tumors
and to counteract the immune system of the host [22-24].
Immunotherapeutic strategies for liver tumors: administration of recombinant cytokines, adoptive transfer of tumor-reactive T cells generated in vitro, gene therapy wi h cytokines and costimulatory molecules, immunotherapy with dendritic cells, stimula-tion with immunogenic vaccines or antibodiesFigur  1
Immunotherapeutic strategies for liver tumors: administration of recombinant cytokines, adoptive transfer of 
tumor-reactive T cells generated in vitro, gene therapy with cytokines and costimulatory molecules, immuno-
therapy with dendritic cells, stimulation with immunogenic vaccines or antibodies.
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antitumor immunity – basic concepts
The immune system is clearly capable of recognizing and
eliminating tumor cells, although cancer cells are consid-
ered as poorly immunogenic [25]. Compelling evidence
suggests that immune cells can eventually play a crucial role
in the control of cancer. First, both occasional spontaneous
tumor regressions have been described in immunocompe-
tent hosts while increased cancer incidence has been
reported in immunocompromised individuals [26]. Sec-
ond, tumor immunity was demonstrated experimentally in
several animal models [27]. Third, the immune system
often recognizes the presence of tumors, as reflected by an
accumulation of immune cells at tumor sites [28].
Despite the ability of the immune system to react against
cancer cells, the presence of a tumor indicates that the devel-
oping cancer can avoid detection or to escape the immune
response [29]. Mechanisms used to elude recognition
include tumor-induced impairment of antigen presentation,
activation of negative co-stimulatory signals, and production
of immunosuppressive factors [30]. In addition, cancer cells
may promote the expansion and/or recruitment of regula-
tory cells that may contribute to the immunosuppressive net-
work; these populations include regulatory T cells (Treg),
myeloid suppressor cells, and distinct subsets of immature
and mature regulatory dendritic cells [31].
All of the previously mentioned mechanisms were shown
to be induced in the liver by hepatitis viruses [32,33] and
a concomitant chronic HCV/HBV infection in HCC
patients would probably make the scenario for immuno-
therapeutic approaches more complicated.
The immunosurveillance and the immunoediting 
hypothesis
In the last 30 years we have witnessed a dramatic change
in basic concepts related to tumor immunology, from the
strict theory of tumor immunosurveillance postulated by
Burnet and Thomas [34,35] to the very recent immunoed-
iting concept developed by Schreiber and colleagues [36].
Using a broader look at tumor immunology, these
authors have elegantly described tumor progression as a
process following three phases: elimination; equilibrium
and, finally, escape, in which tumor cells develop several
strategies to avoid their immune-mediated elimination.
The variety of processes by which tumors evade the
immune response is surprisingly large. Even though can-
cer cells express new or inappropriate antigens, tumors of
diverse origin develop common and/or unique mecha-
nisms that enable them to escape from the immune sys-
tem.
The liver: an immunological privileged organ
Mechanisms of tolerance and their implications in cancer
are of central interest in immunology. The liver is an espe-
cial organ for its immunological privileged status which is
a consequence of several unique immunological proper-
ties causing antigen tolerance rather than immunity
[37,38] and relative resistance against liver allograft rejec-
tion [39], allowing that 20% of allotransplanted patients
could be withdrawn from long-term immunosuppression
[40]. Aggressive autoimmune hepatitis is a somewhat
uncommon clinical manifestation of systemic autoim-
mune disease [41]. Moreover, it has been observed in ani-
mal models that naïve liver reactive T cells ignore antigens
derived from or expressed in the liver [42], generating tol-
erance to them [37]. It is important to note that effector T-
cells alone may not be sufficient for disease induction
without additional inflammatory and costimulatory sig-
nals. A potential role for TLR3 has been reported as one of
the critical mechanisms of hepatic immune privilege [43].
As it was excellently reviewed by Abe and Thomson [38],
liver immunoprivilege properties are likely due to its
unique repertoire of antigen-presenting cell (APC) popu-
lations, consisting of Kupffer cells (KCs), liver sinusoidal
endothelial cells (LSECs) and dendritic cells (DCs). KCs
represent 80–90% of liver resident macrophages and are
very efficient in clearing LPS from gut-derived blood circu-
lation but less efficient in activating CD4+ cells. LSECs
were shown to efficiently separate leukocytes from hepa-
tocytes [44], are able to express factors involved in T cell
death, induce differentiation of CD4+ towards the Th2
anti-inflammatory phenotype and were found to co-stim-
ulate Tregs and inhibit allogeneic T cells. DCs are located
in portal areas or circulate through liver sinusoids towards
lymph draining vessels, and upon maturation increase
their expression levels of IL-12 and CCR7, two molecules
involved in CD4+ T cell differentiation towards the Th1
pro-inflammatory phenotype and in DC trafficking
towards secondary lymphoid organs, respectively. From
all liver APCs, DCs are the most potent to elicit immune
responses. Due to the fact that KCs and LSECs constitu-
tively express IL-10 and TGF-beta anti-inflammatory
cytokines, T cell differentiation is affected and APC matu-
ration inhibited in the liver [45,46]. As a consequence, the
DCs are less immunostimulatory than in spleen [47,48].
In addition, hepatic stellate cells (also known as Ito cells)
were shown to be involved in liver immunological proc-
esses only in case of chronic liver injury. They are induced
to transdifferentiate into myofibroblasts and to secrete a
number of cytokines and chemokines, such as transform-
ing growth factor beta (TGF-beta) [49,50]. In fact, acti-
vated hepatic stellate cells have been shown to closely
interact with lymphocytes [51] and to have potent anti-
gen-presenting properties [52]. Furthermore, stellate cells
from hepatitis patients have been shown to get further
activated by lymphocyte proximity, especially by CD8+
cells, and to phagocyte CD45+ cells [53]. Those facts sug-
gest that stellate cells are likely implicated in the down-Page 3 of 18
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cirrhosis and might also be involved in HCC. These find-
ings open new therapeutic opportunities aimed to specif-
ically targeting hepatic stellate cells in advanced cirrhosis
and HCC.
Finally, when HCC coexists with HBV/HCV derived cir-
rhosis, these viruses as shown in chronic hepatitis, would
likely exert direct and indirect effects on further downreg-
ulation of the immune response through complex and not
fully understood mechanisms. They might influence the
activity of hepatic stellate cells as well as that of resident
and recruited immune cells, such us DCs, through direct
viral protein interaction [54-57]. As reviewed by Liu et al.
[33] in chronic B/C-viral hepatitis a reduction in the mye-
loid and plasmacytoid DC liver populations, down-regu-
lation in IL-12 and IFN-gamma levels, an up-regulation of
IL-10 and an impairment in DCs capacity to prime naïve
T cells may account for the insufficient immune response
observed. Similarly, a reduction in circulating DC num-
bers was found in the peripheral blood of patients with
either chronic-B-hepatitis [58] or chronic-C-hepatitis
[59,60]. HBV/HCV viruses would likely contribute to the
DC impaired allostimulatory and IL-12 production capac-
ities observed in HCC patients [61], although this remains
to be elucidated.
Hepatic tumors escape from the immune response
Hepatic tumors use two main strategies to escape from the
immune response – attack and defense – the first is
designed to attack the immune cells, hence avoiding their
antitumor action and the other to defend tumor cells by
enabling them to pass unnoticed by the immune response
(Table 1).
Attack strategies
Fas ligand (FasL), a type II transmembrane protein
reported to induce apoptosis of Fas-bearing cells [62] was
shown to confer immunological privilege to certain tis-
sues and organs such as eye, placenta and central nervous
system [63-65]. More recently, the interaction of FasL or
its secreted isoform (sFASL) produced by tumor cells, with
their specific Fas receptor, expressed on T lymphocytes,
was implicated in tumor cell evasion from immune sur-
veillance [66]. The α-fetoprotein (AFP), an oncofetal pro-
tein overexpressed in some HCC, was shown to induce
Fas-L and tumor necrosis factor [TNF]-related apoptosis
expression in HCC Bel7402 cells, as well as TRAIL receptor
and Fas in lymphocytes [67,68]. Another pathway devel-
oped to attack immune cells involves the interaction of
PD-1 (programmed death-1) with its ligands PD-L1 and
PD-L2. Immunotherapy with an expression plasmid
encoding the extracellular domain of PD-1 (sPD-1) in
H22 HCC cells was shown to improve the immune
response against tumors [69]. One further mechanism
might implicate Galectin-1 (Gal-1) – a β-galactoside bind-
ing protein with immunoregulatory properties, which is
known to play a role in cytotoxic immune cells elimina-
tion. It is likely that Gal-1 contributes to tumor immune
escape by killing activated T cells [70,71]. In fact, the
expression of Gal-1 was shown to be induced in primary
HLF, HuH7 and HepG2 cells [72].
Defense strategies
The pressure that the immune system exerts on the growth
of tumor cells seems to have led them to develop several
protection mechanisms against any immune attack. It has
been shown that human HCC-related factors not only
induce and expand the regulatory CD4+CD25+ T cell
population (Tregs), but also enhance their suppressor
ability [73]. A high prevalence of Tregs infiltrating HCC
seems to be an unfavorable prognostic indicator [74].
Another mechanism frequently used by tumors is the
down-regulation of MHC-I [75], B7-1/B7-2 co-stimula-
tory molecules [76] or transporter associated with antigen
processing (TAP)1/2 molecules in human HCC [77]. In
addition, HCC cells might escape from CTL-induced
apoptosis by increasing Bcl-2 and decreasing Bcl-xs
Table 1: Mechanisms of hepatic tumor-immune escape.
Attack Defense
System Mechanism Ref. System Mechanism Ref.
Fas/FasL T-cell apoptosis 66 Tregs Immunosuppression 73
PD-1/PD-1L T-cell apoptosis 69 MHC-I Antigen presentation 75
Galectin-1 T-cell apoptosis 72 B7-1/B7-2 Antigen presentation 76
IDO Immunosuppression 82
Two main strategies to escape from the immune response attack and defense have been demonstrated for HCC in experimental and/or clinical 
setting. Fas: CD95; FasL: CD95L; PD-1: programmed death-1; PD-1L: programmed death-1 ligand; Tregs: Regulatory T cells; IDO: Indoleamine 2,3 
dioxygenase.Page 4 of 18
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important member of the inhibitor of apoptosis (IAP)
family [79,80].
Indoleamine 2,3 dioxygenase (IDO) catalyses the degra-
dation of the essential amino acid tryptophan and synthe-
sizes immunosuppressive metabolites [81]. Larrea and
colleagues [82] reported that IDO constitutes an impor-
tant mediator of peripheral immune tolerance in chronic
hepatitis C virus (HCV) infection. Induction of IDO
expression may reduce T-cell reactivity to viral antigens in
chronic HCV infection and may also influence the
immune response against HCC in patients chronically
infected with HCV. Understanding of the immune-escape
mechanisms should help us to design immunotherapy
protocols to increase the efficacy of therapeutic success.
Systemic use of immunostimulatory cytokines
There is a broad experience regarding the use of cytokines
to induce immune and inflammatory responses against
cancer [83,84]. Cytokines have been shown to act through
different mechanisms: i) stimulation of antitumor
immune responses; ii) induction of tumor cell apoptosis
(e.g. through induction of TRAIL) [85]; iii) interference in
uncontrolled proliferation of cancer cells, and iv) anti-
angiogenesis.
One of the most explored cytokines is interferon alpha
(IFN-α) [86,87]. The IFN-α antitumor mechanism of
action includes direct effect on tumor cells, induction of
lymphocyte and macrophage cytotoxic activities and anti-
angiogenesis [88,89]. Two controlled trials comparing
IFN-α with symptomatic treatment in patients with HCC
were reported. In one of them the use of high doses of
IFN-α (50 MU/m2, tiw) resulted in a response rate of 36%
[90]. In the other trial, in which lower doses of IFN-α (3
MU/m2, tiw) were administered, the response rate was
poor (7%) [91]. Even though it is clear that the different
responses are related to the administered doses, the toxic-
ity associated with the higher IFN-α dose is not accepta-
ble, especially for patients with end-stage liver disease.
Nevertheless, systemic administration of IFN-α [92] or
IFN-β [93] should be considered as a supportive treatment
after hepatectomy or tumor ablation, which may prevent
or delay tumor relapses in patients with HCC [94]. A com-
bination of IFN-α and chemotherapy was applied to
patients for treatment of advanced HCC [95,96] and met-
astatic CRC to the liver [97]; however, randomized con-
trolled studies failed to demonstrate that combination
protocol results in improved outcome when compared to
chemotherapy treatment alone [98,99].
Interleukin-2, an immunostimulatory cytokine, has been
administered alone or in combination with other treat-
ments against liver tumors. The non-controlled nature of
most studies precludes from any definitive conclusion.
Systemic IL-2 was able to produce objective responses
against HCC when given alone [100] or in combination
with melatonin [101] or lymphokine activated killer
(LAK) cells [102]. On the other hand, hepatic artery infu-
sion of interleukin 2, with or without chemotherapy,
induced objective remissions in 5% to 15% of liver metas-
tases from CRC [95,103,104]. In a phase II clinical trial,
Correale and colleagues showed that the combination of
polychemotherapy with granulocyte macrophage colony-
stimulating (GM-CSF) factor and low-dose IL-2 in color-
ectal carcinoma patients, results in high number of objec-
tive responses and low toxicity [105].
There is one report on combination of hepatic trans-arte-
rial chemotherapy with IFNγ plus IL-2 in patients with
advanced HCC [106]. The achieved objective responses
highlight some biological effect of this treatment combi-
nation. In another study, when IL-2 was administered
together with IFNγ and GM-CSF to advanced HCC
patients, clinical results were poor [107]. However, in
spite of some stimulating results, the clinical development
of IL-2 has been proved unsuitable because in parallel to
their efficacy the results involved severe toxicity, including
systemic vascular leak syndrome.
No trials were reported on the application of other
cytokines such as IL-12, TNFα, or TRAIL, known to have a
potential effect against primary or metastatic liver cancer
in humans. Nevertheless, concerns were raised following
reports on the development of severe toxicity after sys-
temic treatment with IL-12 or TNFα [108,109] in other
type of tumors.
Although being able to obtain some positive outcomes in
the treatment of liver tumors, systemic application of
cytokines is accompanied by toxic effects which can be
overcome by local delivery. A possible role of some of the
immunostimulatory cytokines, e.g. IL-12, could be rea-
sonable in the context of vaccination as an adjuvant
administered at low doses.
Immunostimulating monoclonal antibodies
In the field of cancer therapy mAbs can act directly against
tumor cells or indirectly by interfering with several proc-
esses such as survival, cellular proliferation or angiogen-
esis. The immunostimulating monoclonal antibodies
which are those corresponding to the latter group, are
defined as a new family of drugs aimed to augment
immune responses. They consist in either agonistic or
antagonistic mAbs which are aimed to bind key immune
system receptors, thereby enhancing antigen presentation,
providing co-stimulation or counteracting immune-regu-
lation [110].Page 5 of 18
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T-cells express several co-signalling molecules, typically
cell-surface glycoproteins classified as co-stimulators or
co-inhibitors [111,112]. The outcome of T-cell responses
depend on the balance between co-stimulatory and co-
inhibitory molecules. Thus, antigenic signalling in the
absence of co-stimulatory molecules results in suboptimal
immune activation and may lead to T-cell deletion or
unresponsiveness. Monoclonal antibodies targeting co-
stimulatory molecules expressed on T-cells may act ago-
nistically, working as surrogate ligands and augmenting T-
cell proliferation and survival. Alternatively, mAbs may
act antagonistically, counteracting the inhibitory effects of
co-inhibitor molecules or Treg-cells.
Costimulation with agonistic mAbs
Diverse costimulatory molecules appear to regulate T-cell
response, working specifically at different time points
[113,114]. Antibodies against CD28 are known to poten-
tiate antitumor immunity in combination with bi-specific
antibodies that bind to both the tumor antigen and the
TCR-CD3 complex [112]. Some anti-CD28 antibodies,
termed superagonist antibodies, can activate T-cells with-
out concomitant TCR engagement. Unfortunately, con-
cerns were raised following reports of severe toxicity in a
Phase I dose-escalation trial with an anti-CD28 mAb
(TGN1412) [115].
Another costimulatory molecule, CD137 (also known as 4-
1BB), is a member of the TNF-receptor superfamily,
expressed in antigen-activated T-cells (CD4+, CD8+, Treg
and NK cells), DCs, cytokine-activated NK cells, eosi-
nophils, mast cells and, intriguingly, endothelial cells of
some metastatic tumors [116-118]. The natural ligand for
CD137 (CD137 ligand) is constitutively produced by acti-
vated APCs. Agonistic anti-CD137 Abs strongly promote
survival of T-cells and prevent activation-induced cell death
[119,120]. Antitumor effects of anti-CD137 mAbs were
first recognized by Melero et al. [121] in established Ag104
sarcoma and P815 mastocytoma. These effects are thought
to be involved in the activation of naive T-cells which are
specific for tumor antigens cross-presented by DCs.
Repeated systemic injections of agonistic anti-CD137, in
two mouse models of CRC, induced tumor eradication in 3
out of 5 mice [122]. Unfortunately, this therapeutic modal-
ity may have serious drawbacks. Niu and colleagues found
that a single injection of anti-CD137 given to BALB/c or
C57BL/6 control mice led to the development of a series of
anomalies such as splenomegaly, lymphadenopathy,
hepatomegaly, multifocal hepatitis, anemia, altered traf-
ficking of B cells and CD8+ T-cells, loss of NK cells, and a
10-fold increase in bone marrow cells bearing the pheno-
type of hematopoietic stem cells [123].
OX40 (also known as CD134 and TNR4) is another mem-
ber of the TNF receptor family, specifically expressed in
activated CD4+ and CD8+ T lymphocyte, B-cells, DCs and
eosinophils [124]. OX40 ligand (OX40L) is expressed in
activated APCs and can also be found in activated T-cells
and in endothelial cells [125]. OX40 seems to be particu-
larly important to ensure T-cell long-term survival, proba-
bly through up-regulation of the anti-apoptotic proteins
Bcl-xL and Bcl-2 [126]. Weinberg [127] showed that sys-
temic OX40 ligation increases tumor immunity, with a
role for CD4+ cells in the B16 melanoma model. Phase I
clinical trials, using a murine anti-human OX40 mAb,
have been initiated in patients with advanced cancer of
multiple tissue origins; however, it can not be adminis-
tered in several repeated doses because of its xenogeneic
nature, which is likely to trigger immune responses
against murine sequences [128].
Thus, agonistic mAbs have been found to produce some
benefits in treatment of liver tumors although their sys-
temic application causes serious undesired secondary
effects. Intratumoral application of low doses of them
might overcome some of the systemic delivery problems.
Counteracting immunoregulation with antagonistic mAbs
The cytotoxic T-lymphocyte-associated protein 4 (CTLA-4,
also known as CD152) is an inhibitory receptor with a
structural homology to the co-stimulatory receptor CD28
[111,129]. Under antigenic stimulation, ligand binding to
CTLA-4 generates inhibitory signals mediating reduction
in T-cell proliferation and in IL-2 secretion. Administra-
tion of antagonistic anti-CTLA-4 mAbs demonstrated
antitumor effects in different murine tumor models
including colon, prostate and renal carcinomas, as well as
fibrosarcoma and lymphoma [130,131].
As mentioned earlier, PD-1 and its ligands B7-H1 (also
known as PD-L1) and B7-DC (also known as PD-L2)
[111,132] deliver inhibitory signals to T cells. Administra-
tion of mAbs anti-PD-1 and B7-H1 produced CTL-medi-
ated antitumor effects in mice [133].
The finding that HCC-associated antigen HAb18G/
CD147, a member of the CD147 family, enhances tumor
invasion and metastasis through induction of matrix met-
alloproteinases [134] led to the development of an anti-
CD147 therapy. By using an orthotopic model of HCC in
nude mice, Ku and colleagues [135] showed that the
application of two different anti-CD147 mAbs (HAb18
and LICARTIN) resulted in consistent inhibition of both
tumor and metastasis growth.
In animal models, immunostimulatory mAbs antitumor
effects were demonstrated when used either alone or in
combination with radiotherapy or chemotherapy
[136,137]. Clinical experience with mAbs is scarce; how-
ever, several immunostimulatory mAbs have now been
introduced in clinical trials and early results suggest thatPage 6 of 18
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toxicity. Therapy with immunostimulatory antibodies
alone or in combination with other strategies should be
carefully designed in order to avoid induction of autoim-
mune toxicity as a consequence of uncontrolled stimula-
tion of the immune system effector arm.
Gene transfer of cytokines and costimulatory 
molecules. Genetic vaccination
Gene therapy is a promising novel therapeutic strategy for
treatment of several heritable and non-heritable human
diseases [138,139]. Since about 20 years ago, when the
first clinical trial was initiated, and after more than 1300
clinical trials performed all around the world http://
www.wiley.co.uk/genmed/clinical/, we learned that the
core concept of gene therapy may be applicable: genes
introduced into patients can be safely expressed [140].
However, we have also learned that vector efficiency in
clinical applications is not as good as expected [141,142].
Cancer represents almost 70% of the clinical trials con-
ducted in patients and 25% of these studies consisted in
the application of cytokine genes.
Gene transfer of immunostimulatory cytokines (e.g. IL-2,
IL-4, IL-6, IL-7; IL-12, INF-γ, TNF-α, GM-CSF) was shown
to overcome the immune tolerance against tumors, facili-
tating their eradication in some cases [143-145] (Table 2).
Two main approaches have been used [144]: i) direct
injection of vectors expressing cytokines/chemokines/cos-
timulatory molecules into tumor lesions, or ii) use of
tumor cells/DCs transduced ex vivo with vectors express-
ing cytokines/costimulatory molecules.
Interleukin 12 (IL-12) is a potent cytokine that showed
antitumor activity in a number of tumor models
[146,147]. Multiple action mechanisms mediating its
activity are known, including the activation of NK cells,
cytotoxic T lymphocytes and the induction of a TH1 type
of response [146]. It also inhibits tumor angiogenesis and
enhances the expression of adhesion molecules on
endothelial cells, thus facilitating the homing of activated
lymphocytes to the tumor [148,149]. However, IL-12 was
shown to eventually induce severe toxicity when adminis-
tered systemically as a recombinant protein [150]. Thus,
unspecific toxic effects of systemic IL-12 administration
might be solved by the use of gene therapy strategies,
allowing local production of IL-12 at the tumor milieu
and resulting in high local levels with low systemic con-
centrations [151]. Consistently, the potential usefulness
of IL-12 gene transfer for liver tumors treatment in animal
models was demonstrated by different groups including
ours [152-154]. We also reported that intratumor injec-
tion of an adenovirus encoding IL-12 genes (AdIL-12)
into rats with orthotopic HCC induced the complete
tumor elimination in the majority of animals [155].
Potent effects of this vector have also been shown in a very
aggressive multifocal HCC model developed in rats, by
treatment with DENA [155,156] as well as in mice bearing
hepatic metastases of colorectal carcinoma [157,158] and
in woodchucks chronically infected with woodchuck hep-
atitis virus (WHV) [159]. The toxicity observed under high
Table 2: Gene transfer immunostimulatory molecules.
Cytokine Mechanism Ref.
IL-2 + IL-12 CTLs 149
IL-10 CD8+ 152
IL-12 NK, CD4+, CD8+ 187
IL-12 + IL-10 NK, CD4+, CD8+, Macrophages, Neutrophils 165
IL-2 CTLs 166
HLA-B7 CTLs 167
IL-12 + IP-10 CD8+, CD4+, NK 161
IL-12 + MIP3α CD8+, CD4+, NK 162
CD40-L CD8+ 168,169
GM-CSF + HSV CD4+, CD8+ 171
CTLs: Cytotoxic T lymphocytes; NK: Natural killer cells.Page 7 of 18
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duction [160]. An encouraging result is that IL-12 gene
transfer in combination with another vector expressing
the chemokine IP-10 (AdIP-10) allowed the reduction in
the AdIL-12 dose with a similar outcome efficacy [161].
The underlying mechanism is the following: lymphocytes
get attracted to tumors due to a local IP-10 expression and
subsequently they are activated by IL-12. In addition, a
combination of IL-12 with MIP3α demonstrated similar
synergistic antitumor effects [162].
The effects of IL-12 gene transfer were assessed in patients
with advanced gastrointestinal carcinomas in a phase I
clinical trial consisting mainly in liver tumors. Patients
were administered with up to 3 intratumor injections of
AdhIL-12[163]. Treatment feasibility and safety were
studied. Even though maximal tolerated dose has not
been reached, some evidence of biological and antitumor
activities were observed. One partial response, two minor
regressions and six stabilizations were achieved. In four
out of 10 patients, a significant lymphocyte infiltrate was
observed in injected tumors.
It has been stated that abnormal elevated levels of Th2
cytokines such as IL-10 are able to skew an immune
response that favors tumor growth [164]. In contrast,
Lopez et al. [165] have recently shown that tumor cell vac-
cines producing a combination of IL-10 and IL-12 act syn-
ergistically in eradicating established CRC, with the
underlying mechanisms being not fully addressed.
Systemic injection of recombinant IL-2 used extensively in
clinical oncology for patients with metastatic renal carci-
noma and melanoma has shown low efficacy and high
toxicity. A phase I-II clinical trial consisting in the admin-
istration of a recombinant adenovirus encoding for IL-2
gene was carried out in patients with advanced digestive
carcinomas [166]. Only one of the treated patients
showed a positive tumor response with necrosis of the
tumor mass.
Molecules such as HLA-B7 are essential to promote specific
T-cell responses. A reduced expression of MHC-I was
observed in CRC. In an attempt to make CRC more visible to
the immune system, Rubin et al [167] carried out a phase I
clinical trial consisting in an indirect intralesional gene trans-
fer of both HLA-B7 and β2-microglobulin into CRC hepatic
metastases. Treatment with a single plasmid construction
encoding for both genes in a lipid formulation (Allovectin-
7) was feasible and safe in 15 patients, however, details
regarding antitumor effect have not been reported. Such an
approach could produce significant therapeutic improve-
ments if aimed to deliver functionally relevant genes.
The interaction between CD40 ligand (CD40L, CD154)
and its receptor CD40, expressed in DCs, is essential for
the initiation of cellular and humoral immune responses.
Gene transfer of CD40-L led to regression of established
CRC [168] and HCC [169] in a CD8+ T cell dependent
manner.
Replication-selective viral agents (oncolytic virotherapy)
hold promise as a novel cancer treatment platform. Onc-
olytic virotherapy is based on the ability of these vectors
to selectively replicate in cancer cells as a result of different
mechanisms of action [170]. This novel class of targeting
viral vectors exerts direct antitumor effects, but can also be
engineered to produce immunostimulatory genes, such as
GM-CSF, augmenting its efficacy. A potent in vivo antitu-
mor effect of an oncolytic vector carrying HSV and GM-
CSF genes has been demonstrated against murine CRC
CT26 and murine HCC Hepa 1.6 [171].
The mutant adenovirus dl1520, also called ONYX-015,
was the first described oncolytic adenovirus [172]. It con-
tains a deletion in the E1B 55 K gene that achieves prefer-
ential replication in cancer cells by different mechanisms.
In the case of liver tumors, this virus showed a partial anti-
tumor effect on murine models but no evident antitumor
effect was found when applied to HCC patients. Two sep-
arate clinical trials showed that ONYX-015 has limited
therapeutic effect as monotherapy in patients with liver
tumors, especially if systemic routes are used [173,174].
Other oncolytic adenoviruses have been developed, and
show promising results in animal models of HCC. How-
ever, their performances in clinical trials have not been
tested so far [175].
In conclusion, gene transfer of cytokines and the use of
oncolytic viruses are two developing immunotherapy
strategies which hold promise in treatment of liver
tumors. The former strategy is being widely applied and
after further improvements might assure sufficient tumor
levels of inflammatory cytokines circumventing toxic sys-
temic effects. The latter strategy is in early stages of devel-
opment and it largely needs to be applied into the clinics.
Immunotherapy with dendritic cells
The armamentarium for immunotherapy protocols has
been boosted by the identification of DCs as protagonists
of antigen presentation [176]. The final outcome of DC
cross-presentation could be either T-cell activation or T-
cell tolerance, depending on its activation/maturation sta-
tus [177]. Thus, while mature DCs are able to induce anti-
tumor immunity, antigen presentation by immature DCs
results in the induction of tolerance [177]. In addition, IL-
4 which is overexpressed in the liver under recurrent hep-
atitis C [178] was shown to influence DCs to induce CD4+
T cell differentiation into the Th2 lineage and to suppress
DC response to IFN-gamma [179]. Up to now, several
clinical studies consisting in the application of DCs were
performed and, as a general outcome, no significant sidePage 8 of 18
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important biological effects showing the augmentation of
cellular immune responses against tumor antigens [180].
Direct injection of DCs into tumor tissue has been
exploited experimentally and clinically with diverse
results [181-183]. Chi KH and colleagues [184] conducted
a phase I trial in patients with advanced HCC after confor-
mal radiotherapy. Intratumoral injections of autologous
immature naïve DCs prior and after radiotherapy resulted
in 2 partial and 4 minor responses. Induction of specific
immune responses against AFPs and enhancement in NK
activity were observed.
DCs ex vivo-engineered to produce IL-12 were shown to
induce antitumor immunity in mice [182,183]. Similar
results were reported after application of DCs genetically
modified to express IL-7 [185] or IL-15 [186]. A phase I
clinical trial consisting in the intratumoral injection of
autologous DCs, transfected with Ad-IL-12, in patients
with metastatic gastrointestinal carcinomas was carried
out [187]. This strategy was feasible and very well toler-
ated in doses up to 50 × 106 DCs. One partial response
and 2 stabilizations were observed. In 3 out of 10 treated
patients, a marked increased in CD8+ T lymphocyte infil-
trates was found, and in 5 of them NK activity was signif-
icantly induced. One of the possible reasons behind the
limited antitumor activity might be that DCs would likely
be retained within the malignant tissue due to increased
intratumoral levels of IL-8 expression as well as other
chemotaxis signals, preventing their mobilization to the
secondary lymphoid organs for further amplification of
immune responses. Consistently, scintigraphic tracking of
injected 111In-labelled DCs showed retention of DCs
inside tumors [188].
As previously discussed, CD40-L is a costimulatory mole-
cule expressed mainly on activated CD4+ T cells, which is
essential for the initiation of antigen-specific T-cell
responses [189]. Crystal and colleagues [190,191] showed
elimination of CRC nodules after intratumoral adminis-
tration of CD40-L exogenously expressing DCs. Although
this approach has not yet been applied in clinical trials, it
seems promising.
Another technique employed to load antigens to DCs
consists in the cellular transfection with mRNA mole-
cules. Chu et al. transfected total mRNA from CT26 CRC
cells to DCs and showed strong specific CTL activity as
well as protective immunity in vivo [192]. Immunization
of CEA-transgenic mice, using mature DCs loaded with an
anti-idiotype antibody that mimics CEA, resulted in a
potent antitumor response against CEA-expressing CRCs,
while immunization with DCs loaded with CEA showed
less potent response [193]. Morse et al. reported a phase I
clinical trial consisting in the administration of autolo-
gous DCs loaded with CEA RNA (peptide CAP-1) into 21
patients with resected CRC liver metastases [194]. The
procedure was well tolerated, one patient had a minor
response, and one had stable disease. More recently, the
same group carried out another phase I study in 14
patients (12 CRC and 2 non-small lung cancer) on the
effects of immunotherapy combined with DCs transduced
with a fowlpox vector encoding CEA and costimulatory
molecules. Immunization of these patients was safe and it
was able to activate potent CEA-specific immune
responses. In a phase I clinical trial with the aim of
increasing the amount of circulating DCs, Fong et al. incu-
bated DCs with the hematopoietic growth factor Flt3 lig-
and before injecting DCs loaded with CEA-derived
peptide into 12 patients with colon or non-small cell lung
cancer [195]. Two patients showed objective responses
and two had stable disease.
Stift and colleagues reported that vaccinations with autolo-
gous DCs pulsed with tumor lysates in a cohort of advanced
cancer patients (including two with HCC) was safe and fea-
sible [196]. Delayed-type hypersensitivity (DTH) skin test
was positive in the majority of vaccination-treated patients
and induction of IFN-γ producing T cells was achieved in 4
other patients (not HCC). Another similar DC-based strategy
was applied by Iwashita and colleagues [197]. They carried
out a phase I clinical trial in patients with advanced HCC.
DC-based strategy consisted in the subcutaneous injection of
DC pulsed with tumor extract in 10 patients. One patient
showed a partial response and in 2 of them AFP levels were
decreased. Seven out of 10 showed positive DTH tests for
KLH. Tamir and colleagues [198] evaluated the effectiveness
of tumor-lysate loaded DC vaccines in the treatment of
advanced CEA-positive CRCs.
Itoh et al. combined both DCs pulsed with a CEA peptide
(restricted to HLA-A24) and adjuvant cytokines (IFN-α and
TNF-α) in the treatment of patients with CEA-expressing
metastatic tumors [199]. Ten HLA-A24 patients with
advanced digestive tract or lung cancer were treated. No sig-
nificant adverse effects were observed and the disease in 2
positive DTH test was stabilized [200]. A few years later,
Ueda and colleagues conducted a phase I clinical study in
which DCs previously pulsed with a CEA-derived peptide
were administered to HLA-A24-restricted patients. Eighteen
compatible patients were enrolled. No severe toxicity was
observed. In some patients, stabilization of the disease and
decrease in CEA levels were reported. Accordingly, patients
with clinical responses were positive in skin tests and devel-
oped specific CTLs [201]. Finally, Babatz and colleagues
demonstrated that immunotherapy with DCs pulsed with
a CEA-derived peptide is able to induce specific IFN-
gamma producing CD8+ T cells [202].
We and others have observed that DCs and NK cell inter-
action plays an important role in tumor immunityPage 9 of 18
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found in patients with metastatic CRC that immunization
with DCs transduced with a fowlpox vector encoding CEA
was able to increase NK activity in 4 of 9 patients [205].
Importantly, increased NK activity was correlated with
clinical response. In order to in vivo-activate DCs and
thereby avoiding ex vivo manipulation, Furumoto et al.
injected MIP3α chemokine together with CpGs inside
CRC tumors [206]. They observed an increase in DC
number within tumors which were finally eradicated
through the development of specific CTLs.
The use of cytokines as a vaccine adjuvant has been shown
to be a promising option for cancer therapy, due to its
potential effectiveness against disseminated disease with-
out causing systemic toxicity [207-211]. However, the
weakness of these strategies lies in: 1) the need of cultur-
ing autologous cancer cells from each patient, 2) the prob-
lems in the selection of positively modified cancer cells, 3)
the lack of an efficient APC activity in tumor cells and, 4)
the limited amount of tumor cells that precludes repeated
immunizations. Investigators have looked into other
strategies to carry cytokines genes or tumor antigens (such
as the use of allogeneic tumor cell lines) but, unfortu-
nately, allogeneic tumor cells may lack sole TAA present
within the patient's own tumor, thus reducing its efficacy.
In conclusion, different strategies involving DCs have been
developed during the lasts years. Although for some of
them no clinical trials have been conducted yet, for other
strategies a proportion of patients responded to treatment
with minor tumor regression or stabilization, with variable
induction of the immune response. Further studies are
required for improving the benefits of manipulating the
main kind of APCs involved in immune reactions.
Contribution of adoptive T-cell therapy 
strategies
In several animal models, solid tumors were shown to be
susceptible to elimination after infusion of large amounts
of tumor-specific T-lymphocytes [212]. However, the
translation of these enthusiastic successes into patients are
not yet feasible, partly due to difficulties in generating
tumor antigen-specific T-cells ex vivo [213].
Adoptive therapy involves the transfer of ex vivo expanded
and stimulated immune effector cells to tumor-bearing
hosts, aiming at augmenting the antitumor immune
response [212,214]. In general, adoptive therapy is accom-
plished by harvesting cells from the peripheral blood, tumor
sites (tumor infiltrating lymphocytes), or draining lymph
nodes from which, the effector cells could eventually be
expanded ex vivo, in either a specific or non-specific fashion.
One of the major aims of the adoptive T-cell therapy is the
identification of tumor-associated antigens (TAAs) that
are ectopically expressed or overexpressed in tumor cells
relative to normal tissues or, tumor-specific antigens
(TSAs) that are expressed exclusively in tumor cells.
Despite aberrant expression of TAAs in tumor cells, many
of these proteins are also expressed at some level in non-
malignant adult tissues and, as a consequence, the
immune system may recognize TAAs as self-antigens and
limit the T-cell immune response. In addition, as previ-
ously discussed the liver immune system usually generates
tolerance to proteins expressed by its own cells and HCC
induces immune response suppression [215]. Moreover,
it was demonstrated that many malignant tumors find the
way of down-regulating, modifying or losing its own anti-
gens, in order to avoid immune recognition [29].
No TSA with high prevalence have been identified for liver
tumors, so far. PLAC-1, which in normal tissues is only
expressed in placenta, was recently found to be expressed
in 1/3rd to 1/4th of the analyzed human HCC samples and
3,8% of patients were shown to present humoral
responses against this antigen [216]. Among TAAs
described in HCC the most important one is AFP. Several
AFP-based immunotherapeutic approaches have been
applied against HCC [217,218]. Additional TAAs recently
found to be expressed in HCC are several members of the
tumor-specific "cancer-testis" antigens (the MAGE, GAGE
and BAGE genes, NY-ESO, CTA, TSPY and FATE/BJ-HCC-
2, among others) [219-221];, Aurora-A [222], SCCA
[223], and Glypican-3. In between them, Glypican-3, a
specific immunomarker for HCC that can be used to dis-
tinguish it from benign hepatocellular mass lesions, is
highly immunogenic in mice and can induce effective
antitumor immunity with no evidence of autoimmunity
[224]. Several TAA antigens are also known for CRC liver
tumors, including CEA and CP1 [225]. Clinical studies
must be conducted in order to evaluate the potential use
of these antigens in immunotherapy for liver tumors.
The lack of TSAs for HCC may be the most important limit
to immunotherapy applications aimed to specifically tar-
get liver tumor cells. Several technological strategies such
as serologic recombinant expression cloning (SEREX),
gene expression profiling and proteomics, are being
applied to discover any of those specific markers [226]
but, until now, the results are limited [227].
Another important negative factor limiting the success of
this type of immunotherapy is the low survival of adop-
tively transferred T-lymphocytes in cancer patients is. Cur-
rently, some strategies are being evaluated to increase the
proliferation rate of transferred T-cells, including pre-
treatment with cyclophosphamide [228].
T cells are the cellular model predominantly chosen for
adoptive cellular therapy, although a role for NK cells and
other cytokine-induced lymphocytes have also beenPage 10 of 18
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notherapy were initiated in cancer soon after the discovery
of IL-2 (in the late 1970s), which enabled large-scale cul-
ture of T cells [229]. Although certain clinical success has
been observed in melanoma, renal cancer, and lymphoma
[230,231], phase II studies in HCC patients have shown
objective response rates of only about 20% [232,233].
To date, no randomized clinical trials, but one, had dem-
onstrated efficacy of adoptive T cell transfer approaches.
Takayama et al. [234] reported benefits of adoptive trans-
fer with an adjuvant setting for HCC after surgical resec-
tion of the primary tumor. In this study, autologous
peripheral blood T cells were pre-cultured in medium sup-
plemented with CD3-specific antibody and IL-2, and cell
infusion was shown to reduce the risk of cancer recurrence
by 41% when compared to a control group receiving only
surgery. However, this trial remains unconfirmed, and the
mechanism involved in the antitumoral effect remains
unknown.
In order to enhance the effector capacity of tumor-specific
T cells, different cytokines such as IL-18 and IL-12, were
tested as potential biological response modifiers in the
setting of adoptive immunotherapy. Nakamori et al. [235]
demonstrated that adoptive transfer of IL-18-transduced
cytotoxic T-lymphocytes in combination with IL-12
showed marked inhibitory effects on primary tumors and
metastasis in a mouse model of orthotopic CRC.
Synergistic effect of combined therapy
Combinatorial strategies against cancer could either con-
sist in a simultaneous application of different immuno-
therapeutic approaches or in a combination of classic
chemo- or radio-therapeutic protocols with immunologic
tools. Some chemotherapeutical agents were shown to
induce upregulation of tumor-associated antigen expres-
sion (such as CEA) or to reduce tumor cell resistance to
specific cytotoxic T lymphocytes. Some of these combina-
tions have been found to produce synergistic rather than
additive effects.
The immune-inhibitory mechanisms developed by tumor
cells, such as overproduction of immunosuppressive
cytokines (TGF-β and IL-10) or induction of Treg cells, are
important obstacles that a successful cancer immuno-
therapy strategy has to face. Inhibition of one or more of
these mechanisms appear to be a good strategy to induce
antitumor immunity [236]. Elimination or inhibition of
Treg activity by low-dose cyclophosphamide [237] or
antibodies against CD25 or CTLA-4 may modify tumor
immunosuppressive microenvironment, thereby increas-
ing the efficacy of immunotherapy.
It has been shown, both in mice and humans, that pre-
treatment with cyclophosphamide, known to induce lym-
phodepletion, results in a sustained function of adop-
tively transferred T-cells. Adoptive transfer efficacy can
also be enhanced by alternative immunotherapies such as
cytokine administration [238] and in some cases by
standard cytotoxic chemotherapy and radiotherapy
[239,240].
Preclinical models support the rationale for combining
cancer vaccines with conventional therapies, such as radi-
ation, chemotherapy, surgery, hormone therapy, as well
as other immunotherapies. One of the most promising
results was obtained from clinical trials combining anti-
bodies against CTLA-4 with other immunotherapies such
as application of GM-CSF-transduced tumor-cell vaccines.
This treatment resulted in the alteration of the intratumor
balance of Tregs-T effector cells and in tumor rejection
[241]. Further research is required to optimize the combi-
nation of different immunotherapies to obtain maximal
clinical benefits.
What have we learned from the clinic? 
Conclusion
Conducting immunotherapy clinical trials in patients
with liver tumors is challenging and several strategies have
been opened for clinical applications. However, the high
efficacy of different immunotherapy strategies at eliminat-
ing liver tumors in animal models is in contrast with the
very limited results achieved in patients. There are many
explanations to why immunotherapy strategies fail or
have little impact on patient survival. In general, for all
solid tumors, the common scenario chosen to test immu-
notherapeutic protocols almost always involves patients
with advanced diseases that precludes, or at least
decreases, the possibility of success. Then, due to the
advanced status of the cancer disease, the immune system
of the majority of treated patients is deteriorated and una-
ble to recognize tumor antigens. For the specific case of
HCC and partially to CRC liver tumors, apart from the
immunological privilege status of the liver, there are some
particular aspects that add further difficulties when aim-
ing for a clinical response such as the immunosuppressant
effect of chronic HBV/HCV infection on cells of the
immune system (e.g. DCs) or complications derived from
developed cirrhosis which usually undermine efforts to
stimulate the immune response. There is a general agree-
ment in that different forms of immunotherapy should be
tested for overall clinical benefits along with conventional
treatment regimens evidencing improvements in survival.
It would be desirable to evaluate the possibility of immu-
notherapy strategies as neoadjuvancy in patients at early
stages of the disease such as after surgical removal of HCC
and hepatic metastases of CRC, two diseases with
increased likelihood of recurrence. Finally, new ways of
long-term local delivery of signals inducing CD4+ T cell
differentiation towards the Th1 lineage or vaccination
against liver tumor antigens would eventually overcomePage 11 of 18
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the impairment or reduced immune response capacity
caused by HBV/HCV viruses.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
MP and VR: The immune system and the induction of
antitumor immunity – basic concepts; Contribution of
adoptive T-cell therapy strategies. JBA: The liver: an immu-
nological privileged organ. OGS and JBA: Immunostimu-
lating monoclonal antibodies. LA and MM:
Immunotherapy with dendritic cells. GM: Introduction;
The liver: an immunological privileged organ; Systemic
use of immunostimulatory cytokines; Gene transfer of
cytokines and costimulatory molecules; Genetic vaccina-
tion; Conclusions.
MG did a deep revision of the English grammar and style
because English is not our native language. CA con-
structed the figure and the tables. MS was involved in the
analysis and revision of the data included in the paper.
GM outlined the topics of the manuscript and invited to
each author to write specific chapters of the paper. All
authors read and approved the final manuscript.
Acknowledgements
We would like to thank Miguel Rizzo and Soledad Arregui for their techni-
cal assistance. GM work is supported in part by grants from Agencia 
Nacional de Promoción Científica y Tecnológica (ANPCyT) (PICT-2005/
34788 and PICTO-CRUP-2005/31179), Agencia Española de Cooperación 
Internacional and Programa Bicentenario-Banco Mundial, Conicyt, Chile 
CTE-06 (MG). LA work is supported in part by Mitzutani Foundation. CA 
and MM are fellows from ANPCyT. GM acknowledges the continuous sup-
port of Mrs. Ines Bemberg.
References
1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics,
2002.  CA Cancer J Clin 2005, 55:74-108.
2. El-Serag HB, Mason AC: Rising Incidence of Hepatocellular Car-
cinoma in the United States.  N Engl J Med 1999, 340:745-750.
3. El-Serag HB, Marrero JA, Rudolph L, Reddy KR: Diagnosis and
treatment of hepatocellular carcinoma.  Gastroenterology 2008,
134:1752-1763.
4. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma.  Lan-
cet 2003, 362:1907-1917.
5. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs
AK, Christensen E, Pagliaro L, Colombo M, Rodes J: Clinical man-
agement of hepatocellular carcinoma. Conclusions of the
Barcelona-2000 EASL conference. European Association for
the Study of the Liver.  J Hepatol 2001, 35:421-430.
6. Bruix J, Sherman M: Management of hepatocellular carcinoma.
Hepatology 2005, 42:1208-1236.
7. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW: Color-
ectal cancer.  Lancet 2005, 365:153-165.
8. Cummings LC, Payes JD, Cooper GS: Survival after hepatic resec-
tion in metastatic colorectal cancer: a population-based
study.  Cancer 2007, 109:718-726.
9. Lorenz M, Staib-Sebler E, Hochmuth K, Heinrich S, Gog C, Vetter G,
Encke A, Muller HH: Surgical resection of liver metastases of
colorectal carcinoma: short and long-term results.  Semin
Oncol 2000, 27:112-119.
10. Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J: Factors
influencing the natural history of colorectal liver metastases.
Lancet 1994, 343:1405-1410.
11. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J,
Boni C, Cortes-Funes H, Cervantes A, Freyer G, et al.: Leucovorin
and fluorouracil with or without oxaliplatin as first-line treat-
ment in advanced colorectal cancer.  J Clin Oncol 2000,
18:2938-2947.
12. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Kara-
sek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L,
Rougier P: Irinotecan combined with fluorouracil compared
with fluorouracil alone as first-line treatment for metastatic
colorectal cancer: a multicentre randomised trial.  Lancet
2000, 355:1041-1047.
13. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK,
Williamson SK, Findlay BP, Pitot HC, Alberts SR: A randomized
controlled trial of fluorouracil plus leucovorin, irinotecan,
and oxaliplatin combinations in patients with previously
untreated metastatic colorectal cancer.  J Clin Oncol 2004,
22:23-30.
14. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ,
Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL:
Irinotecan plus fluorouracil and leucovorin for metastatic
colorectal cancer. Irinotecan Study Group.  N Engl J Med 2000,
343:905-914.
15. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth
J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe
G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan,
fluorouracil, and leucovorin for metastatic colorectal can-
cer.  N Engl J Med 2004, 350:2335-2342.
16. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A,
Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E:
Cetuximab monotherapy and cetuximab plus irinotecan in
irinotecan-refractory metastatic colorectal cancer.  N Engl J
Med 2004, 351:337-345.
17. Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE, Morris
JC: Progress on new vaccine strategies for the immuno-
therapy and prevention of cancer.  J Clin Invest 2004,
113:1515-1525.
18. Gilboa E: The promise of cancer vaccines.  Nat Rev Cancer 2004,
4:401-411.
19. Unitt E, Marshall A, Gelson W, Rushbrook SM, Davies S, Vowler SL,
Morris LS, Coleman N, Alexander GJ: Tumour lymphocytic infil-
trate and recurrence of hepatocellular carcinoma following
liver transplantation.  J Hepatol 2006, 45:246-253.
20. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H:
CD8+ T cells infiltrated within cancer cell nests as a prognos-
tic factor in human colorectal cancer.  Cancer Res 1998,
58:3491-3494.
21. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-
Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F,
Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F: Type,
density, and location of immune cells within human colorec-
tal tumors predict clinical outcome.  Science 2006,
313:1960-1964.
22. Bertoletti A, Ferrari C: Kinetics of the immune response during
HBV and HCV infection.  Hepatology 2003, 38:4-13.
23. Rehermann B, Nascimbeni M: Immunology of hepatitis B virus
and hepatitis C virus infection.  Nat Rev Immunol 2005, 5:215-229.
24. Dustin LB, Rice CM: Flying under the radar: the immunobiol-
ogy of hepatitis C.  Annu Rev Immunol 2007, 25:71-99.
25. Rosenberg SA: Progress in human tumour immunology and
immunotherapy.  Nature 2001, 411:380-384.
26. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Sch-
reiber RD: IFNgamma and lymphocytes prevent primary
tumour development and shape tumour immunogenicity.
Nature 2001, 410:1107-1111.
27. Dunn GP, Old LJ, Schreiber RD: The three Es of cancer immu-
noediting.  Annu Rev Immunol 2004, 22:329-360.
28. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M,
Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN,
Rubin SC, Coukos G: Intratumoral T cells, recurrence, and sur-
vival in epithelial ovarian cancer.  N Engl J Med 2003,
348:203-213.
29. Croci DO, Zacarias Fluck MF, Rico MJ, Matar P, Rabinovich GA, Scha-
rovsky OG: Dynamic cross-talk between tumor and immunePage 12 of 18
(page number not for citation purposes)
Journal of Biomedical Science 2009, 16:30 http://www.jbiomedsci.com/content/16/1/30cells in orchestrating the immunosuppressive network at the
tumor microenvironment.  Cancer Immunol Immunother 2007,
56:1687-1700.
30. Rivoltini L, Carrabba M, Huber V, Castelli C, Novellino L, Dalerba P,
Mortarini R, Arancia G, Anichini A, Fais S, Parmiani G: Immunity to
cancer: attack and escape in T lymphocyte-tumor cell inter-
action.  Immunol Rev 2002, 188:97-113.
31. Zou W: Regulatory T cells, tumour immunity and immuno-
therapy.  Nat Rev Immunol 2006, 6:295-307.
32. Nattermann J, Zimmermann H, Iwan A, von Lilienfeld-Toal M, Leifeld
L, Nischalke HD, Langhans B, Sauerbruch T, Spengler U: Hepatitis C
virus E2 and CD81 interaction may be associated with
altered trafficking of dendritic cells in chronic hepatitis C.
Hepatology 2006, 44:945-954.
33. Liu B, Woltman AM, Janssen HL, Boonstra A: Modulation of den-
dritic cell function by persistent viruses.  J Leukoc Biol 2008,
85(2):205-214.
34. Burnet FM: The concept of immunological surveillance.  Prog
Exp Tumor Res 1970, 13:1-27.
35. Thomas L: On immunosurveillance in human cancer.  Yale J Biol
Med 1982, 55:329-333.
36. Dunn GP, Old LJ, Schreiber RD: The immunobiology of cancer
immunosurveillance and immunoediting.  Immunity 2004,
21:137-148.
37. Luth S, Huber S, Schramm C, Buch T, Zander S, Stadelmann C, Bruck
W, Wraith DC, Herkel J, Lohse AW: Ectopic expression of neural
autoantigen in mouse liver suppresses experimental autoim-
mune neuroinflammation by inducing antigen-specific
Tregs.  J Clin Invest 2008, 118:3403-3410.
38. Abe M, Thomson AW: Antigen processing and presentation in
the liver.  In Liver Immunology: Principles and Practice Edited by: Ger-
shwin ME, Vierling JM, Manns MP. Totowa: Humana Press Inc;
2007:486. 
39. Kamada N, Davies HS, Roser B: Reversal of transplantation
immunity by liver grafting.  Nature 1981, 292:840-842.
40. Seyfert-Margolis V, Turka LA: Marking a path to transplant tol-
erance.  J Clin Invest 2008, 118:2684-2686.
41. Diamantis I, Boumpas DT: Autoimmune hepatitis: evolving con-
cepts.  Autoimmun Rev 2004, 3:207-214.
42. Voehringer D, Blaser C, Grawitz AB, Chisari FV, Buerki K, Pircher H:
Break of T cell ignorance to a viral antigen in the liver
induces hepatitis.  J Immunol 2000, 165:2415-2422.
43. Lang KS, Georgiev P, Recher M, Navarini AA, Bergthaler A, Heiken-
walder M, Harris NL, Junt T, Odermatt B, Clavien PA, Pircher H,
Akira S, Hengartner H, Zinkernagel RM: Immunoprivileged status
of the liver is controlled by Toll-like receptor 3 signaling.  J
Clin Invest 2006, 116:2456-2463.
44. Limmer A, Sacher T, Alferink J, Kretschmar M, Schonrich G, Nichter-
lein T, Arnold B, Hammerling GJ: Failure to induce organ-specific
autoimmunity by breaking of tolerance: importance of the
microenvironment.  Eur J Immunol 1998, 28:2395-2406.
45. Crispe IN: Hepatic T cells and liver tolerance.  Nat Rev Immunol
2003, 3:51-62.
46. Bissell DM, Wang SS, Jarnagin WR, Roll FJ: Cell-specific expression
of transforming growth factor-beta in rat liver. Evidence for
autocrine regulation of hepatocyte proliferation.  J Clin Invest
1995, 96:447-455.
47. De Creus A, Abe M, Lau AH, Hackstein H, Raimondi G, Thomson
AW: Low TLR4 expression by liver dendritic cells correlates
with reduced capacity to activate allogeneic T cells in
response to endotoxin.  J Immunol 2005, 174:2037-2045.
48. Pillarisetty VG, Shah AB, Miller G, Bleier JI, DeMatteo RP: Liver den-
dritic cells are less immunogenic than spleen dendritic cells
because of differences in subtype composition.  J Immunol 2004,
172:1009-1017.
49. De Minicis S, Seki E, Uchinami H, Kluwe J, Zhang Y, Brenner DA,
Schwabe RF: Gene expression profiles during hepatic stellate
cell activation in culture and in vivo.  Gastroenterology 2007,
132:1937-1946.
50. Friedman SL: Liver fibrosis – from bench to bedside.  J Hepatol
2003, 38(Suppl 1):S38-53.
51. Muhanna N, Horani A, Doron S, Safadi R: Lymphocyte-hepatic
stellate cell proximity suggests a direct interaction.  Clin Exp
Immunol 2007, 148:338-347.
52. Viñas O, Bataller R, Sancho-Bru P, Ginès P, Berenguer C, Enrich C,
Nicolás JM, Ercilla G, Gallart T, Vives J, Arroyo V, Rodés J: Human
hepatic stellate cells show features of antigen-presenting
cells and stimulate lymphocyte proliferation.  Hepatology 2003,
38:919-929.
53. Muhanna N, Doron S, Wald O, Horani A, Eid A, Pappo O, Friedman
SL, Safadi R: Activation of hepatic stellate cells after phagocy-
tosis of lymphocytes: A novel pathway of fibrogenesis.  Hepa-
tology 2008, 48:963-977.
54. Bain C, Fatmi A, Zoulim F, Zarski JP, Trepo C, Inchauspe G:
Impaired allostimulatory function of dendritic cells in
chronic hepatitis C infection.  Gastroenterology 2001,
120:512-524.
55. Sarobe P, Lasarte JJ, Zabaleta A, Arribillaga L, Arina A, Melero I, Bor-
ras-Cuesta F, Prieto J: Hepatitis C virus structural proteins
impair dendritic cell maturation and inhibit in vivo induction
of cellular immune responses.  J Virol 2003, 77:10862-10871.
56. Waggoner SN, Hall CH, Hahn YS: HCV core protein interaction
with gC1q receptor inhibits Th1 differentiation of CD4+ T
cells via suppression of dendritic cell IL-12 production.  J Leu-
koc Biol 2007, 82:1407-1419.
57. Zimmermann M, Flechsig C, La Monica N, Tripodi M, Adler G, Diko-
poulos N: Hepatitis C virus core protein impairs in vitro prim-
ing of specific T cell responses by dendritic cells and
hepatocytes.  J Hepatol 2008, 48:51-60.
58. Duan XZ, Zhuang H, Wang M, Li HW, Liu JC, Wang FS: Decreased
numbers and impaired function of circulating dendritic cell
subsets in patients with chronic hepatitis B infection (R2).  J
Gastroenterol Hepatol 2005, 20:234-242.
59. Kanto T, Inoue M, Miyatake H, Sato A, Sakakibara M, Yakushijin T,
Oki C, Itose I, Hiramatsu N, Takehara T, Kasahara A, Hayashi N:
Reduced numbers and impaired ability of myeloid and plas-
macytoid dendritic cells to polarize T helper cells in chronic
hepatitis C virus infection.  J Infect Dis 2004, 190:1919-1926.
60. Wertheimer AM, Bakke A, Rosen HR: Direct enumeration and
functional assessment of circulating dendritic cells in
patients with liver disease.  Hepatology 2004, 40:335-345.
61. Ninomiya T, Akbar SM, Masumoto T, Horiike N, Onji M: Dendritic
cells with immature phenotype and defective function in the
peripheral blood from patients with hepatocellular carci-
noma.  J Hepatol 1999, 31:323-331.
62. Curtin JF, Cotter TG: Live and let die: regulatory mechanisms
in Fas-mediated apoptosis.  Cell Signal 2003, 15:983-992.
63. Griffith TS, Yu X, Herndon JM, Green DR, Ferguson TA: CD95-
induced apoptosis of lymphocytes in an immune privileged
site induces immunological tolerance.  Immunity 1996, 5:7-16.
64. Ohshima K, Nakashima M, Sonoda K, Kikuchi M, Watanabe T:
Expression of RCAS1 and FasL in human trophoblasts and
uterine glands during pregnancy: the possible role in
immune privilege.  Clin Exp Immunol 2001, 123:481-486.
65. Griffith TS, Ferguson TA: The role of FasL-induced apoptosis in
immune privilege.  Immunol Today 1997, 18:240-244.
66. Song E, Chen J, Ouyang N, Su F, Wang M, Heemann U: Soluble Fas
ligand released by colon adenocarcinoma cells induces host
lymphocyte apoptosis: an active mode of immune evasion in
colon cancer.  Br J Cancer 2001, 85:1047-1054.
67. Li M, Liu X, Zhou S, Li P, Li G: Effects of alpha fetoprotein on
escape of Bel 7402 cells from attack of lymphocytes.  BMC
Cancer 2005, 5:96.
68. Li MS, Ma QL, Chen Q, Liu XH, Li PF, Du GG, Li G: Alpha-fetopro-
tein triggers hepatoma cells escaping from immune surveil-
lance through altering the expression of Fas/FasL and tumor
necrosis factor related apoptosis-inducing ligand and its
receptor of lymphocytes and liver cancer cells.  World J Gastro-
enterol 2005, 11:2564-2569.
69. He YF, Zhang GM, Wang XH, Zhang H, Yuan Y, Li D, Feng ZH:
Blocking programmed death-1 ligand-PD-1 interactions by
local gene therapy results in enhancement of antitumor
effect of secondary lymphoid tissue chemokine.  J Immunol
2004, 173:4919-4928.
70. Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM,
Bravo A, Mordoh J, Fainboim L, Podhajcer OL, Rabinovich GA: Tar-
geted inhibition of galectin-1 gene expression in tumor cells
results in heightened T cell-mediated rejection; A potential
mechanism of tumor-immune privilege.  Cancer Cell 2004,
5:241-251.
71. Rabinovich GA, Rubinstein N, Matar P, Rozados V, Gervasoni S, Scha-
rovsky GO: The antimetastatic effect of a single low dose ofPage 13 of 18
(page number not for citation purposes)
Journal of Biomedical Science 2009, 16:30 http://www.jbiomedsci.com/content/16/1/30cyclophosphamide involves modulation of galectin-1 and
Bcl-2 expression.  Cancer Immunol Immunother 2002, 50:597-603.
72. Kondoh N, Hada A, Ryo A, Shuda M, Arai M, Matsubara O, Kimura F,
Wakatsuki T, Yamamoto M: Activation of Galectin-1 gene in
human hepatocellular carcinoma involves methylation-sen-
sitive complex formations at the transcriptional upstream
and downstream elements.  Int J Oncol 2003, 23:1575-1583.
73. Cao M, Cabrera R, Xu Y, Firpi R, Zhu H, Liu C, Nelson DR: Hepa-
tocellular carcinoma cell supernatants increase expansion
and function of CD4(+)CD25(+) regulatory T cells.  Lab Invest
2007, 87:582-590.
74. Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T,
Nakajima A, Hirohashi S: FOXP3+ regulatory T cells affect the
development and progression of hepatocarcinogenesis.  Clin
Cancer Res 2007, 13:902-911.
75. Kurokohchi K, Carrington M, Mann DL, Simonis TB, Alexander-Miller
MA, Feinstone SM, Akatsuka T, Berzofsky JA: Expression of HLA
class I molecules and the transporter associated with antigen
processing in hepatocellular carcinoma.  Hepatology 1996,
23:1181-1188.
76. Fujiwara K, Higashi T, Nouso K, Nakatsukasa H, Kobayashi Y,
Uemura M, Nakamura S, Sato S, Hanafusa T, Yumoto Y, Naito I, Shi-
ratori Y: Decreased expression of B7 costimulatory mole-
cules and major histocompatibility complex class-I in human
hepatocellular carcinoma.  J Gastroenterol Hepatol 2004,
19:1121-1127.
77. Matsui M, Machida S, Itani-Yohda T, Akatsuka T: Downregulation
of the proteasome subunits, transporter, and antigen pres-
entation in hepatocellular carcinoma, and their restoration
by interferon-gamma.  J Gastroenterol Hepatol 2002, 17:897-907.
78. Chiu CT, Yeh TS, Hsu JC, Chen MF: Expression of Bcl-2 family
modulated through p53-dependent pathway in human hepa-
tocellular carcinoma.  Dig Dis Sci 2003, 48:670-676.
79. Fields AC, Cotsonis G, Sexton D, Santoianni R, Cohen C: Survivin
expression in hepatocellular carcinoma: correlation with
proliferation, prognostic parameters, and outcome.  Mod
Pathol 2004, 17:1378-1385.
80. Kannangai R, Wang J, Liu QZ, Sahin F, Torbenson M: Survivin over-
expression in hepatocellular carcinoma is associated with
p53 dysregulation.  Int J Gastrointest Cancer 2005, 35:53-60.
81. Munn DH: Indoleamine 2,3-dioxygenase, tumor-induced tol-
erance and counter-regulation.  Curr Opin Immunol 2006,
18:220-225.
82. Larrea E, Riezu-Boj JI, Gil-Guerrero L, Casares N, Aldabe R, Sarobe
P, Civeira MP, Heeney JL, Rollier C, Verstrepen B, Wakita T, Borrás-
Cuesta F, Lasarte JJ, Prieto J: Upregulation of indoleamine 2,3-
dioxygenase in hepatitis C virus infection.  J Virol 2007,
81:3662-3666.
83. Dranoff G: Cytokines in cancer pathogenesis and cancer ther-
apy.  Nat Rev Cancer 2004, 4:11-22.
84. Musiani P, Modesti A, Giovarelli M, Cavallo F, Colombo MP, Lollini PL,
Forni G: Cytokines, tumour-cell death and immunogenicity: a
question of choice.  Immunol Today 1997, 18:32-36.
85. Humphreys RC, Halpern W: Trail receptors: targets for cancer
therapy.  Adv Exp Med Biol 2008, 615:127-158.
86. Ahmed FY, Cassidy J: The treatment of advanced colorectal
cancer with interferon-alpha: a review.  Expert Opin Investig
Drugs 1999, 8:13-18.
87. Kirkwood J: Cancer immunotherapy: the interferon-alpha
experience.  Semin Oncol 2002, 29:18-26.
88. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ:
Interferons alpha and beta down-regulate the expression of
basic fibroblast growth factor in human carcinomas.  Proc Natl
Acad Sci USA 1995, 92:4562-4566.
89. Belardelli F, Ferrantini M, Proietti E, Kirkwood JM: Interferon-alpha
in tumor immunity and immunotherapy.  Cytokine Growth Factor
Rev 2002, 13:119-134.
90. Lai CL, Lau JY, Wu PC, Ngan H, Chung HT, Mitchell SJ, Corbett TJ,
Chow AW, Lin HJ: Recombinant interferon-alpha in inopera-
ble hepatocellular carcinoma: a randomized controlled trial.
Hepatology 1993, 17:389-394.
91. Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, Ayuso C,
Vargas V, Rodes J, Bruix J: Randomized controlled trial of inter-
feron treatment for advanced hepatocellular carcinoma.
Hepatology 2000, 31:54-58.
92. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O,
Shiomi S, Tamori A, Oka H, Igawa S, Kuroki T, Kinoshita H: Effects
of long-term postoperative interferon-alpha therapy on int-
rahepatic recurrence after resection of hepatitis C virus-
related hepatocellular carcinoma. A randomized, controlled
trial.  Ann Intern Med 2001, 134:963-967.
93. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota
A, Chayama K, Murashima N, Kumada H: Interferon beta pre-
vents recurrence of hepatocellular carcinoma after com-
plete resection or ablation of the primary tumor-A
prospective randomized study of hepatitis C virus-related
liver cancer.  Hepatology 2000, 32:228-232.
94. Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, Koike Y,
Yoshida H, Omata M: Interferon therapy after tumor ablation
improves prognosis in patients with hepatocellular carci-
noma associated with hepatitis C virus.  Ann Intern Med 2003,
138:299-306.
95. Patt YZ, Hassan MM, Lozano RD, Brown TD, Vauthey JN, Curley SA,
Ellis LM: Phase II trial of systemic continuous fluorouracil and
subcutaneous recombinant interferon Alfa-2b for treatment
of hepatocellular carcinoma.  J Clin Oncol 2003, 21:421-427.
96. Sakon M, Nagano H, Dono K, Nakamori S, Umeshita K, Yamada A,
Kawata S, Imai Y, Iijima S, Monden M: Combined intraarterial 5-
fluorouracil and subcutaneous interferon-alpha therapy for
advanced hepatocellular carcinoma with tumor thrombi in
the major portal branches.  Cancer 2002, 94:435-442.
97. Grem JL, Jordan E, Robson ME, Binder RA, Hamilton JM, Steinberg
SM, Arbuck SG, Beveridge RA, Kales AN, Miller JA, et al.: Phase II
study of fluorouracil, leucovorin, and interferon alfa-2a in
metastatic colorectal carcinoma.  J Clin Oncol 1993,
11:1737-1745.
98. Hausmaninger H, Moser R, Samonigg H, Mlineritsch B, Schmidt H,
Pecherstorfer M, Fridrik M, Kopf C, Nitsche D, Kaider A, Ludwig H:
Biochemical modulation of 5-fluorouracil by leucovorin with
or without interferon-alpha-2c in patients with advanced
colorectal cancer: final results of a randomised phase III
study.  Eur J Cancer 1999, 35:380-385.
99. Fountzilas G, Zisiadis A, Dafni U, Konstantaras C, Hatzitheoharis G,
Papavramidis S, Bousoulegas A, Basdanis G, Giannoulis E, Dokmetzi-
oglou J, et al.: Fluorouracil and leucovorin with or without
interferon alfa-2a as adjuvant treatment, in patients with
high-risk colon cancer: a randomized phase III study con-
ducted by the Hellenic Cooperative Oncology Group.  Oncol-
ogy 2000, 58:227-236.
100. Palmieri G, Montella L, Milo M, Fiore R, Biondi E, Bianco AR, Marti-
gnetti A: Ultra-low-dose interleukin-2 in unresectable hepato-
cellular carcinoma.  Am J Clin Oncol 2002, 25:224-226.
101. Aldeghi R, Lissoni P, Barni S, Ardizzoia A, Tancini G, Piperno A, Pozzi
M, Ricci G, Conti A, Maestroni GJ: Low-dose interleukin-2 subcu-
taneous immunotherapy in association with the pineal hor-
mone melatonin as a first-line therapy in locally advanced or
metastatic hepatocellular carcinoma.  Eur J Cancer 1994,
30A:167-170.
102. Ishikawa T, Imawari M, Moriyama T, Ohnishi S, Matsuhashi N, Suzuki
G, Takaku F: Immunotherapy of hepatocellular carcinoma
with autologous lymphokine-activated killer cells and/or
recombinant interleukin-2.  J Cancer Res Clin Oncol 1988,
114:283-290.
103. Okuno K, Hirohata T, Nakamura K, Jinnai H, Shigeoka H, Koh K,
Shindo K, Yasutomi M: Hepatic arterial infusions of interleukin-
2-based immunochemotherapy in the treatment of unre-
sectable liver metastases from colorectal cancer.  Clin Ther
1993, 15:672-683.
104. Lygidakis NJ, Savanis G, Pothoulakis J, Kapetanakis A: Transarterial
locoregional immunostimulation and chemotherapy in
patients with unresectable secondary liver tumours.  Antican-
cer Res 1994, 14:643-646.
105. Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, Placa ML,
Intrivici C, Aquino A, Micheli L, Nencini C, Ferrari F, Giorgi G, Bon-
massar E, Francini G: Chemo-immunotherapy of metastatic
colorectal carcinoma with gemcitabine plus FOLFOX 4 fol-
lowed by subcutaneous granulocyte macrophage colony-
stimulating factor and interleukin-2 induces strong immuno-
logic and antitumor activity in metastatic colon cancer
patients.  J Clin Oncol 2005, 23:8950-8958.Page 14 of 18
(page number not for citation purposes)
Journal of Biomedical Science 2009, 16:30 http://www.jbiomedsci.com/content/16/1/30106. Lygidakis NJ, Kosmidis P, Ziras N, Parissis J, Kyparidou E: Combined
transarterial targeting locoregional immunotherapy-chem-
otherapy for patients with unresectable hepatocellular carci-
noma: a new alternative for an old problem.  J Interferon
Cytokine Res 1995, 15:467-472.
107. Reinisch W, Holub M, Katz A, Herneth A, Lichtenberger C, Schoni-
ger-Hekele M, Waldhoer T, Oberhuber G, Ferenci P, Gangl A, Muel-
ler C: Prospective pilot study of recombinant granulocyte-
macrophage colony-stimulating factor and interferon-
gamma in patients with inoperable hepatocellular carci-
noma.  J Immunother 2002, 25:489-499.
108. Hieber U, Heim ME: Tumor necrosis factor for the treatment
of malignancies.  Oncology 1994, 51:142-153.
109. Merino D, Lalaoui N, Morizot A, Solary E, Micheau O: TRAIL in
cancer therapy: present and future challenges.  Expert Opin
Ther Targets 2007, 11:1299-1314.
110. Zhu Y, Chen L: Cancer therapeutic monoclonal antibodies tar-
geting lymphocyte co-stimulatory pathways.  Curr Opin Investig
Drugs 2003, 4:691-695.
111. Greenwald RJ, Freeman GJ, Sharpe AH: The B7 family revisited.
Annu Rev Immunol 2005, 23:515-548.
112. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA,
McGowan P, Linsley PS: Costimulation of antitumor immunity
by the B7 counterreceptor for the T lymphocyte molecules
CD28 and CTLA-4.  Cell 1992, 71:1093-1102.
113. Riley JL, June CH: The CD28 family: a T-cell rheostat for ther-
apeutic control of T-cell activation.  Blood 2005, 105:13-21.
114. Bertram EM, Dawicki W, Watts TH: Role of T cell costimulation
in anti-viral immunity.  Semin Immunol 2004, 16:185-196.
115. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A,
Brunner MD, Panoskaltsis N: Cytokine storm in a phase 1 trial
of the anti-CD28 monoclonal antibody TGN1412.  N Engl J
Med 2006, 355:1018-1028.
116. Myers LM, Vella AT: Interfacing T-cell effector and regulatory
function through CD137 (4-1BB) co-stimulation.  Trends Immu-
nol 2005, 26:440-446.
117. Pollok KE, Kim YJ, Zhou Z, Hurtado J, Kim KK, Pickard RT, Kwon BS:
Inducible T cell antigen 4-1BB. Analysis of expression and
function.  J Immunol 1993, 150:771-781.
118. Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L: NK1.1
cells express 4-1BB (CDw137) costimulatory molecule and
are required for tumor immunity elicited by anti-4-1BB
monoclonal antibodies.  Cell Immunol 1998, 190:167-172.
119. Shuford WW, Klussman K, Tritchler DD, Loo DT, Chalupny J, Siadak
AW, Brown TJ, Emswiler J, Raecho H, Larsen CP, Pearson TC, Led-
better JA, Aruffo A, Mittler RS: 4-1BB costimulatory signals pref-
erentially induce CD8+ T cell proliferation and lead to the
amplification in vivo of cytotoxic T cell responses.  J Exp Med
1997, 186:47-55.
120. Takahashi C, Mittler RS, Vella AT: Cutting edge: 4-1BB is a bona
fide CD8 T cell survival signal.  J Immunol 1999, 162:5037-5040.
121. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hell-
strom KE, Mittler RS, Chen L: Monoclonal antibodies against the
4-1BB T-cell activation molecule eradicate established
tumors.  Nat Med 1997, 3:682-685.
122. Mazzolini G, Murillo O, Atorrasagasti C, Dubrot J, Tirapu I, Rizzo M,
Arina A, Alfaro C, Azpilicueta A, Berasain C, Perez-Gracia JL,
Gonzalez A, Melero I: Immunotherapy and immunoescape in
colorectal cancer.  World J Gastroenterol 2007, 13:5822-5831.
123. Niu L, Strahotin S, Hewes B, Zhang B, Zhang Y, Archer D, Spencer T,
Dillehay D, Kwon B, Chen L, Vella AT, Mittler RS: Cytokine-medi-
ated disruption of lymphocyte trafficking, hemopoiesis, and
induction of lymphopenia, anemia, and thrombocytopenia in
anti-CD137-treated mice.  J Immunol 2007, 178:4194-4213.
124. Croft M: Costimulation of T cells by OX40, 4-1BB, and CD27.
Cytokine Growth Factor Rev 2003, 14:265-273.
125. Watts TH: TNF/TNFR family members in costimulation of T
cell responses.  Annu Rev Immunol 2005, 23:23-68.
126. Rogers PR, Song J, Gramaglia I, Killeen N, Croft M: OX40 promotes
Bcl-xL and Bcl-2 expression and is essential for long-term
survival of CD4 T cells.  Immunity 2001, 15:445-455.
127. Weinberg AD, Rivera MM, Prell R, Morris A, Ramstad T, Vetto JT,
Urba WJ, Alvord G, Bunce C, Shields J: Engagement of the OX-40
receptor in vivo enhances antitumor immunity.  J Immunol
2000, 164:2160-2169.
128. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L: Immu-
nostimulatory monoclonal antibodies for cancer therapy.
Nat Rev Cancer 2007, 7:95-106.
129. Teft WA, Kirchhof MG, Madrenas J: A molecular perspective of
CTLA-4 function.  Annu Rev Immunol 2006, 24:65-97.
130. Leach DR, Krummel MF, Allison JP: Enhancement of antitumor
immunity by CTLA-4 blockade.  Science 1996, 271:1734-1736.
131. Chambers CA, Kuhns MS, Egen JG, Allison JP: CTLA-4-mediated
inhibition in regulation of T cell responses: mechanisms and
manipulation in tumor immunotherapy.  Annu Rev Immunol
2001, 19:565-594.
132. Chen L: Co-inhibitory molecules of the B7-CD28 family in the
control of T-cell immunity.  Nat Rev Immunol 2004, 4:336-347.
133. Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, Rietz
C, Flies DB, Lau JS, Zhu G, Tamada K, Chen L: Blockade of B7-H1
and PD-1 by monoclonal antibodies potentiates cancer ther-
apeutic immunity.  Cancer Res 2005, 65:1089-1096.
134. Xu J, Xu HY, Zhang Q, Song F, Jiang JL, Yang XM, Mi L, Wen N, Tian
R, Wang L, Yao H, Feng Q, Zhang Y, Xing JL, Zhu P, Chen ZN:
HAb18G/CD147 functions in invasion and metastasis of
hepatocellular carcinoma.  Mol Cancer Res 2007, 5:605-614.
135. Ku XM, Liao CG, Li Y, Yang XM, Yang B, Yao XY, Wang L, Kong LM,
Zhao P, Chen ZN: Epitope mapping of series of monoclonal
antibodies against the hepatocellular carcinoma-associated
antigen HAb18G/CD147.  Scand J Immunol 2007, 65:435-443.
136. Mokyr MB, Kalinichenko T, Gorelik L, Bluestone JA: Realization of
the therapeutic potential of CTLA-4 blockade in low-dose
chemotherapy-treated tumor-bearing mice.  Cancer Res 1998,
58:5301-5304.
137. Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP,
Formenti SC: Immune-mediated inhibition of metastases after
treatment with local radiation and CTLA-4 blockade in a
mouse model of breast cancer.  Clin Cancer Res 2005, 11:728-734.
138. Miller AD: Human gene therapy comes of age.  Nature 1992,
357:455-460.
139. Mulligan RC: The basic science of gene therapy.  Science 1993,
260:926-932.
140. Edelstein ML, Abedi MR, Wixon J, Edelstein RM: Gene therapy clin-
ical trials worldwide 1989–2004-an overview.  J Gene Med 2004,
6:597-602.
141. Aiuti A, Bachoud-Lévi AC, Blesch A, Brenner MK, Cattaneo F, Chi-
occa EA, Gao G, High KA, Leen AM, Lemoine NR, McNeish IA,
Meneguzzi G, Peschanski M, Roncarolo MG, Strayer DS, Tuszynski
MH, Waxman DJ, Wilson JM: Progress and prospects: gene ther-
apy clinical trials (part 2).  Gene Ther 2007, 14:1555-1563.
142. Alexander BL, Ali RR, Alton EW, Bainbridge JW, Braun S, Cheng SH,
Flotte TR, Gaspar HB, Grez M, Griesenbach U, Kaplitt MG, Ott MG,
Seger R, Simons M, Thrasher AJ, Thrasher AZ, Ylä-Herttuala S:
Progress and prospects: gene therapy clinical trials (part 1).
Gene Ther 2007, 14:1439-1447.
143. Cao L, Kulmburg P, Veelken H, Mackensen A, Mezes B, Lindemann A,
Mertelsmann R, Rosenthal FM: Cytokine gene transfer in cancer
therapy.  Stem Cells 1998, 16(Suppl 1):251-260.
144. Qian C, Liu XY, Prieto J: Therapy of cancer by cytokines medi-
ated by gene therapy approach.  Cell Res 2006, 16:182-188.
145. Schmidt-Wolf GD, Schmidt-Wolf IG: Cytokines and gene ther-
apy.  Immunol Today 1995, 16:173-175.
146. Trinchieri G: Interleukin-12 and the regulation of innate resist-
ance and adaptive immunity.  Nat Rev Immunol 2003, 3:133-146.
147. Colombo MP, Trinchieri G: Interleukin-12 in anti-tumor immu-
nity and immunotherapy.  Cytokine Growth Factor Rev 2002,
13:155-168.
148. Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S,
Kleinman HK, Reaman GH, Tosato G: Human interferon-induci-
ble protein 10 is a potent inhibitor of angiogenesis in vivo.  J
Exp Med 1995, 182:155-162.
149. Mazzolini G, Narvaiza I, Bustos M, Duarte M, Tirapu I, Bilbao R, Qian
C, Prieto J, Melero I: Alpha(v)beta(3) integrin-mediated aden-
oviral transfer of interleukin-12 at the periphery of hepatic
colon cancer metastases induces VCAM-1 expression and T-
cell recruitment.  Mol Ther 2001, 3:665-672.
150. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins
MB, Sosman JA, Dutcher JP, Vogelzang NJ, Ryan JL: Effects of single-
dose interleukin-12 exposure on interleukin-12-associated
toxicity and interferon-gamma production.  Blood 1997,
90:2541-2548.Page 15 of 18
(page number not for citation purposes)
Journal of Biomedical Science 2009, 16:30 http://www.jbiomedsci.com/content/16/1/30151. Mazzolini G, Prieto J, Melero I: Gene therapy of cancer with
interleukin-12.  Curr Pharm Des 2003, 9:1981-1991.
152. Adris S, Klein S, Jasnis M, Chuluyan E, Ledda M, Bravo A, Carbone C,
Chernajovsky Y, Podhajcer O: IL-10 expression by CT26 colon
carcinoma cells inhibits their malignant phenotype and
induces a T cell-mediated tumor rejection in the context of
a systemic Th2 response.  Gene Ther 1999, 6:1705-1712.
153. Mazzolini G, Qian C, Xie X, Sun Y, Lasarte JJ, Drozdzik M, Prieto J:
Regression of colon cancer and induction of antitumor
immunity by intratumoral injection of adenovirus expressing
interleukin-12.  Cancer Gene Ther 1999, 6:514-522.
154. Adris S, Chuluyan E, Bravo A, Berenstein M, Klein S, Jasnis M, Car-
bone C, Chernajovsky Y, Podhajcer OL: Mice vaccination with
interleukin 12-transduced colon cancer cells potentiates
rejection of syngeneic non-organ-related tumor cells.  Cancer
Res 2000, 60:6696-6703.
155. Barajas M, Mazzolini G, Genove G, Bilbao R, Narvaiza I, Schmitz V,
Sangro B, Melero I, Qian C, Prieto J: Gene therapy of orthotopic
hepatocellular carcinoma in rats using adenovirus coding for
interleukin 12.  Hepatology 2001, 33:52-61.
156. Barajas M, Mazzolini G, Genove G, Bilbao R, Narvaiza I, Schmitz V,
Sangro B, Melero I, Qian C, Prieto J: Gene therapy of orthotopic
hepatocellular carcinoma in rats using adenovirus coding for
interleukin 12.  Hepatology 2001, 33:52-61.
157. Mazzolini G, Qian C, Narvaiza I, Barajas M, Borras-Cuesta F, Xie X,
Duarte M, Melero I, Prieto J: Adenoviral gene transfer of inter-
leukin 12 into tumors synergizes with adoptive T cell ther-
apy both at the induction and effector level.  Hum Gene Ther
2000, 11:113-125.
158. Caruso M, Pham-Nguyen K, Kwong YL, Xu B, Kosai KI, Finegold M,
Woo SL, Chen SH: Adenovirus-mediated interleukin-12 gene
therapy for metastatic colon carcinoma.  Proc Natl Acad Sci USA
1996, 93:11302-11306.
159. Pützer BM, Stiewe T, Rödicker F, Schildgen O, Rühm S, Dirsch O, Fie-
dler M, Damen U, Tennant B, Scherer C, Graham FL, Roggendorf M:
Large nontransplanted hepatocellular carcinoma in wood-
chucks: treatment with adenovirus-mediated delivery of
interleukin 12/B7.1 genes.  J Natl Cancer Inst 2001, 93:472-479.
160. Mazzolini G, Narvaiza I, Perez-Diez A, Rodriguez-Calvillo M, Qian C,
Sangro B, Ruiz J, Prieto J, Melero I: Genetic heterogeneity in the
toxicity to systemic adenoviral gene transfer of interleukin-
12.  Gene Ther 2001, 8:259-267.
161. Narvaiza I, Mazzolini G, Barajas M, Duarte M, Zaratiegui M, Qian C,
Melero I, Prieto J: Intratumoral coinjection of two adenovi-
ruses, one encoding the chemokine IFN-gamma-inducible
protein-10 and another encoding IL-12, results in marked
antitumoral synergy.  J Immunol 2000, 164:3112-3122.
162. Mazzolini G, Narvaiza I, Martinez-Cruz LA, Arina A, Barajas M,
Galofre JC, Qian C, Mato JM, Prieto J, Melero I: Pancreatic cancer
escape variants that evade immunogene therapy through
loss of sensitivity to IFNgamma-induced apoptosis.  Gene Ther
2003, 10:1067-1078.
163. Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J, Herrero I, Benito
A, Larrache J, Pueyo J, Subtil JC, Olagüe C, Sola J, Sádaba B, Lacasa C,
Melero I, Qian C, Prieto J: Phase I trial of intratumoral injection
of an adenovirus encoding interleukin-12 for advanced diges-
tive tumors.  J Clin Oncol 2004, 22:1389-1397.
164. Clerici M, Shearer GM, Clerici E: Cytokine dysregulation in inva-
sive cervical carcinoma and other human neoplasias: time to
consider the TH1/TH2 paradigm.  J Natl Cancer Inst 1998,
90:261-263.
165. Lopez MV, Adris SK, Bravo AI, Chernajovsky Y, Podhajcer OL: IL-12
and IL-10 expression synergize to induce the immune-medi-
ated eradication of established colon and mammary tumors
and lung metastasis.  J Immunol 2005, 175:5885-5894.
166. Gilly FN, Beaujard A, Bienvenu J, Trillet Lenoir V, Glehen O, Thou-
venot D, Malcus C, Favrot M, Dumontet C, Lombard-Bohas C, Garbit
F, Gueugniaud PY, Vignal J, Aymard M, Touraine Moulin F, Roos M,
Pavirani A, Courtney M: Gene therapy with Adv-IL-2 in unre-
sectable digestive cancer: phase I-II study, intermediate
report.  Hepatogastroenterology 1999, 46(Suppl 1):1268-1273.
167. Rubin J, Galanis E, Pitot HC, Richardson RL, Burch PA, Charboneau
JW, Reading CC, Lewis BD, Stahl S, Akporiaye ET, Harris DT: Phase
I study of immunotherapy of hepatic metastases of colorec-
tal carcinoma by direct gene transfer of an allogeneic histo-
compatibility antigen, HLA-B7.  Gene Ther 1997, 4:419-425.
168. Sun Y, Peng D, Lecanda J, Schmitz V, Barajas M, Qian C, Prieto J: In
vivo gene transfer of CD40 ligand into colon cancer cells
induces local production of cytokines and chemokines,
tumor eradication and protective antitumor immunity.  Gene
Ther 2000, 7:1467-1476.
169. Schmitz V, Barajas M, Wang L, Peng D, Duarte M, Prieto J, Qian C:
Adenovirus-mediated CD40 ligand gene therapy in a rat
model of orthotopic hepatocellular carcinoma.  Hepatology
2001, 34:72-81.
170. Liu TC, Kirn D: Gene therapy progress and prospects cancer:
oncolytic viruses.  Gene Ther 2008, 15(12):877-884.
171. Malhotra S, Kim T, Zager J, Bennett J, Ebright M, D'Angelica M, Fong
Y: Use of an oncolytic virus secreting GM-CSF as combined
oncolytic and immunotherapy for treatment of colorectal
and hepatic adenocarcinomas.  Surgery 2007, 141:520-529.
172. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L,
Nye JA, Sampson-Johannes A, Fattaey A, McCormick F: An adeno-
virus mutant that replicates selectively in p53-deficient
human tumor cells.  Science 1996, 274:373-376.
173. Habib N, Salama H, Abd El Latif Abu Median A, Isac Anis I, Abd Al Aziz
RA, Sarraf C, Mitry R, Havlik R, Seth P, Hartwigsen J, Bhushan R,
Nicholls J, Jensen S: Clinical trial of E1B-deleted adenovirus
(dl1520) gene therapy for hepatocellular carcinoma.  Cancer
Gene Ther 2002, 9:254-259.
174. Hamid O, Varterasian ML, Wadler S, Hecht JR, Benson A 3rd, Galanis
E, Uprichard M, Omer C, Bycott P, Hackman RC, Shields AF: Phase
II trial of intravenous CI-1042 in patients with metastatic
colorectal cancer.  J Clin Oncol 2003, 21:1498-1504.
175. Hernandez-Alcoceba R, Sangro B, Prieto J: Gene therapy of liver
cancer.  Ann Hepatol 2007, 6:5-14.
176. Banchereau J, Steinman RM: Dendritic cells and the control of
immunity.  Nature 1998, 392:245-252.
177. Reis e Sousa C: Dendritic cells in a mature age.  Nat Rev Immunol
2006, 6:476-483.
178. Aoudjehane L, Pissaia A Jr, Scatton O, Podevin P, Massault PP,
Chouzenoux S, Soubrane O, Calmus Y, Conti F: Interleukin-4
induces the activation and collagen production of cultured
human intrahepatic fibroblasts via the STAT-6 pathway.  Lab
Invest 2008, 88:973-985.
179. Sriram U, Biswas C, Behrens EM, Dinnall JA, Shivers DK, Monestier
M, Argon Y, Gallucci S: IL-4 suppresses dendritic cell response
to type I interferons.  J Immunol 2007, 179:6446-6455.
180. Nestle FO, Farkas A, Conrad C: Dendritic-cell-based therapeu-
tic vaccination against cancer.  Curr Opin Immunol 2005,
17:163-169.
181. Melcher A, Todryk S, Bateman A, Chong H, Lemoine NR, Vile RG:
Adoptive transfer of immature dendritic cells with autolo-
gous or allogeneic tumor cells generates systemic antitumor
immunity.  Cancer Res 1999, 59:2802-2805.
182. Nishioka Y, Hirao M, Robbins PD, Lotze MT, Tahara H: Induction of
systemic and therapeutic antitumor immunity using intratu-
moral injection of dendritic cells genetically modified to
express interleukin 12.  Cancer Res 1999, 59:4035-4041.
183. Melero I, Duarte M, Ruiz J, Sangro B, Galofre J, Mazzolini G, Bustos
M, Qian C, Prieto J: Intratumoral injection of bone-marrow
derived dendritic cells engineered to produce interleukin-12
induces complete regression of established murine trans-
plantable colon adenocarcinomas.  Gene Ther 1999,
6:1779-1784.
184. Chi KH, Liu SJ, Li CP, Kuo HP, Wang YS, Chao Y, Hsieh SL: Combi-
nation of conformal radiotherapy and intratumoral injection
of adoptive dendritic cell immunotherapy in refractory
hepatoma.  J Immunother 2005, 28:129-135.
185. Miller PW, Sharma S, Stolina M, Butterfield LH, Luo J, Lin Y, Dohad-
wala M, Batra RK, Wu L, Economou JS, Dubinett SM: Intratumoral
administration of adenoviral interleukin 7 gene-modified
dendritic cells augments specific antitumor immunity and
achieves tumor eradication.  Hum Gene Ther 2000, 11:53-65.
186. Vera M, Razquin N, Prieto J, Melero I, Fortes P, Gonzalez-Aseg-
uinolaza G: Intratumoral injection of dendritic cells trans-
duced by an SV40-based vector expressing interleukin-15
induces curative immunity mediated by CD8+ T lym-
phocytes and NK cells.  Mol Ther 2005, 12:950-959.
187. Mazzolini G, Alfaro C, Sangro B, Feijoó E, Ruiz J, Benito A, Tirapu I,
Arina A, Sola J, Herraiz M, Lucena F, Olagüe C, Subtil J, Quiroga J,
Herrero I, Sádaba B, Bendandi M, Qian C, Prieto J, Melero I: Intratu-Page 16 of 18
(page number not for citation purposes)
Journal of Biomedical Science 2009, 16:30 http://www.jbiomedsci.com/content/16/1/30moral injection of dendritic cells engineered to secrete inter-
leukin-12 by recombinant adenovirus in patients with
metastatic gastrointestinal carcinomas.  J Clin Oncol 2005,
23:999-1010.
188. Feijoó E, Alfaro C, Mazzolini G, Serra P, Peñuelas I, Arina A, Huarte
E, Tirapu I, Palencia B, Murillo O, Ruiz J, Sangro B, Richter JA, Prieto
J, Melero I: Dendritic cells delivered inside human carcinomas
are sequestered by interleukin-8.  Int J Cancer 2005,
116:275-281.
189. Grewal IS, Flavell RA: CD40 and CD154 in cell-mediated immu-
nity.  Annu Rev Immunol 1998, 16:111-135.
190. Kikuchi T, Miyazawa N, Moore MA, Crystal RG: Tumor regression
induced by intratumor administration of adenovirus vector
expressing CD40 ligand and naive dendritic cells.  Cancer Res
2000, 60:6391-6395.
191. Kikuchi T, Moore MA, Crystal RG: Dendritic cells modified to
express CD40 ligand elicit therapeutic immunity against
preexisting murine tumors.  Blood 2000, 96:91-99.
192. Chu XY, Chen LB, Zang J, Wang JH, Zhang Q, Geng HC: Effect of
bone marrow-derived monocytes transfected with RNA of
mouse colon carcinoma on specific antitumor immunity.
World J Gastroenterol 2005, 11:760-763.
193. Saha A, Chatterjee SK, Foon KA, Primus FJ, Sreedharan S, Mohanty K,
Bhattacharya-Chatterjee M: Dendritic cells pulsed with an anti-
idiotype antibody mimicking carcinoembryonic antigen
(CEA) can reverse immunological tolerance to CEA and
induce antitumor immunity in CEA transgenic mice.  Cancer
Res 2004, 64:4995-5003.
194. Morse MA, Deng Y, Coleman D, Hull S, Kitrell-Fisher E, Nair S, Sch-
lom J, Ryback ME, Lyerly HK: A Phase I study of active immuno-
therapy with carcinoembryonic antigen peptide (CAP-1)-
pulsed, autologous human cultured dendritic cells in patients
with metastatic malignancies expressing carcinoembryonic
antigen.  Clin Cancer Res 1999, 5:1331-1338.
195. Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, Davis MM, Eng-
leman EG: Altered peptide ligand vaccination with Flt3 ligand
expanded dendritic cells for tumor immunotherapy.  Proc Natl
Acad Sci USA 2001, 98:8809-8814.
196. Stift A, Friedl J, Dubsky P, Bachleitner-Hofmann T, Schueller G,
Zontsich T, Benkoe T, Radelbauer K, Brostjan C, Jakesz R, Gnant M:
Dendritic cell-based vaccination in solid cancer.  J Clin Oncol
2003, 21:135-142.
197. Iwashita Y, Tahara K, Goto S, Sasaki A, Kai S, Seike M, Chen CL,
Kawano K, Kitano S: A phase I study of autologous dendritic
cell-based immunotherapy for patients with unresectable
primary liver cancer.  Cancer Immunol Immunother 2003,
52:155-161.
198. Tamir A, Basagila E, Kagahzian A, Jiao L, Jensen S, Nicholls J, Tate P,
Stamp G, Farzaneh F, Harrison P, Stauss H, George AJ, Habib N, Lech-
ler RI, Lombardi G: Induction of tumor-specific T-cell
responses by vaccination with tumor lysate-loaded dendritic
cells in colorectal cancer patients with carcinoembryonic-
antigen positive tumors.  Cancer Immunol Immunother 2007,
56:2003-2016.
199. Morse MA, Deng Y, Coleman D, Hull S, Kitrell-Fisher E, Nair S, Sch-
lom J, Ryback ME, Lyerly HK: A Phase I study of active immuno-
therapy with carcinoembryonic antigen peptide (CAP-1)-
pulsed, autologous human cultured dendritic cells in patients
with metastatic malignancies expressing carcinoembryonic
antigen.  Clin Cancer Res 1999, 5:1331-1338.
200. Itoh T, Ueda Y, Kawashima I, Nukaya I, Fujiwara H, Fuji N, Yamashita
T, Yoshimura T, Okugawa K, Iwasaki T, Ideno M, Takesako K, Mitsu-
hashi M, Orita K, Yamagishi H: Immunotherapy of solid cancer
using dendritic cells pulsed with the HLA-A24-restricted
peptide of carcinoembryonic antigen.  Cancer Immunol Immu-
nother 2002, 51:99-106.
201. Ueda Y, Itoh T, Nukaya I, Kawashima I, Okugawa K, Yano Y,
Yamamoto Y, Naitoh K, Shimizu K, Imura K, Fuji N, Fujiwara H,
Ochiai T, Itoi H, Sonoyama T, Hagiwara A, Takesako K, Yamagishi H:
Dendritic cell-based immunotherapy of cancer with carci-
noembryonic antigen-derived, HLA-A24-restricted CTL
epitope: Clinical outcomes of 18 patients with metastatic
gastrointestinal or lung adenocarcinomas.  Int J Oncol 2004,
24:909-917.
202. Babatz J, Rollig C, Lobel B, Folprecht G, Haack M, Gunther H, Kohne
CH, Ehninger G, Schmitz M, Bornhauser M: Induction of cellular
immune responses against carcinoembryonic antigen in
patients with metastatic tumors after vaccination with
altered peptide ligand-loaded dendritic cells.  Cancer Immunol
Immunother 2006, 55:268-276.
203. Kalinski P, Mailliard RB, Giermasz A, Zeh HJ, Basse P, Bartlett DL,
Kirkwood JM, Lotze MT, Herberman RB: Natural killer-dendritic
cell cross-talk in cancer immunotherapy.  Expert Opin Biol Ther
2005, 5:1303-1315.
204. Rodriguez-Calvillo M, Duarte M, Tirapu I, Berraondo P, Mazzolini G,
Qian C, Prieto J, Melero I: Upregulation of natural killer cells
functions underlies the efficacy of intratumorally injected
dendritic cells engineered to produce interleukin-12.  Exp
Hematol 2002, 30:195-204.
205. Osada T, Clay T, Hobeika A, Lyerly HK, Morse MA: NK cell activa-
tion by dendritic cell vaccine: a mechanism of action for clin-
ical activity.  Cancer Immunol Immunother 2006, 55:1122-1131.
206. Furumoto K, Soares L, Engleman EG, Merad M: Induction of potent
antitumor immunity by in situ targeting of intratumoral
DCs.  J Clin Invest 2004, 113:774-783.
207. Morse M, Langer L, Starodub A, Hobeika A, Clay T, Lyerly HK: Cur-
rent immunotherapeutic strategies in colon cancer.  Surg
Oncol Clin N Am 2007, 16:873-900.
208. von Mehren M: Colorectal cancer vaccines: what we know and
what we don't yet know.  Semin Oncol 2005, 32:76-84.
209. Prieto J, Qian C, Sangro B, Melero I, Mazzolini G: Biologic therapy
of liver tumors.  Surg Clin North Am 2004, 84:673-696.
210. Chiriva-Internati M, Grizzi F, Wachtel MS, Jenkins M, Ferrari R, Cobos
E, Frezza EE: Biological treatment for liver tumor and new
potential biomarkers.  Dig Dis Sci 2008, 53:836-843.
211. Elkord E, Hawkins RE, Stern PL: Immunotherapy for gastrointes-
tinal cancer: current status and strategies for improving effi-
cacy.  Expert Opin Biol Ther 2008, 8:385-395.
212. Ho WY, Yee C, Greenberg PD: Adoptive therapy with CD8(+)
T cells: it may get by with a little help from its friends.  J Clin
Invest 2002, 110:1415-1417.
213. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME: Adop-
tive cell transfer: a clinical path to effective cancer immuno-
therapy.  Nat Rev Cancer 2008, 8:299-308.
214. June CH: Principles of adoptive T cell cancer therapy.  J Clin
Invest 2007, 117:1204-1212.
215. Pang YL, Zhang HG, Peng JR, Pang XW, Yu S, Xing Q, Yu X, Gong L,
Yin YH, Zhang Y, Chen WF: The immunosuppressive tumor
microenvironment in hepatocellular carcinoma.  Cancer Immu-
nol Immunother 2008.
216. Dong XY, Peng JR, Ye YJ, Chen HS, Zhang LJ, Pang XW, Li Y, Zhang
Y, Wang S, Fant ME, Yin YH, Chen WF: Plac1 is a tumor-specific
antigen capable of eliciting spontaneous antibody responses
in human cancer patients.  Int J Cancer 2008, 122:2038-2043.
217. Grimm CF, Ortmann D, Mohr L, Michalak S, Krohne TU, Meckel S,
Eisele S, Encke J, Blum HE, Geissler M: Mouse alpha-fetoprotein-
specific DNA-based immunotherapy of hepatocellular carci-
noma leads to tumor regression in mice.  Gastroenterology 2000,
119:1104-1112.
218. Vollmer CM Jr, Eilber FC, Butterfield LH, Ribas A, Dissette VB, Koh
A, Montejo LD, Lee MC, Andrews KJ, McBride WH, Glaspy JA, Econ-
omou JS: Alpha-fetoprotein-specific genetic immunotherapy
for hepatocellular carcinoma.  Cancer Res 1999, 59:3064-3067.
219. Chen CH, Chen GJ, Lee HS, Huang GT, Yang PM, Tsai LJ, Chen DS,
Sheu JC: Expressions of cancer-testis antigens in human hepa-
tocellular carcinomas.  Cancer Lett 2001, 164:189-195.
220. Kobayashi Y, Higashi T, Nouso K, Nakatsukasa H, Ishizaki M, Kaney-
oshi T, Toshikuni N, Kariyama K, Nakayama E, Tsuji T: Expression
of MAGE, GAGE and BAGE genes in human liver diseases:
utility as molecular markers for hepatocellular carcinoma.  J
Hepatol 2000, 32:612-617.
221. Yamashita N, Ishibashi H, Hayashida K, Kudo J, Takenaka K, Itoh K,
Niho Y: High frequency of the MAGE-1 gene expression in
hepatocellular carcinoma.  Hepatology 1996, 24:1437-1440.
222. Jeng YM, Peng SY, Lin CY, Hsu HC: Overexpression and amplifi-
cation of Aurora-A in hepatocellular carcinoma.  Clin Cancer
Res 2004, 10:2065-2071.
223. Giannelli G, Marinosci F, Sgarra C, Lupo L, Dentico P, Antonaci S:
Clinical role of tissue and serum levels of SCCA antigen in
hepatocellular carcinoma.  Int J Cancer 2005, 116:579-583.
224. Nakatsura T, Komori H, Kubo T, Yoshitake Y, Senju S, Katagiri T,
Furukawa Y, Ogawa M, Nakamura Y, Nishimura Y: Mouse homo-Page 17 of 18
(page number not for citation purposes)
Journal of Biomedical Science 2009, 16:30 http://www.jbiomedsci.com/content/16/1/30Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
logue of a novel human oncofetal antigen, glypican-3, evokes
T-cell-mediated tumor rejection without autoimmune reac-
tions in mice.  Clin Cancer Res 2004, 10:8630-8640.
225. Liu FF, Dong XY, Pang XW, Xing Q, Wang HC, Zhang HG, Li Y, Yin
YH, Fant M, Ye YJ, Shen DH, Zhang Y, Wang S, Chen WF: The spe-
cific immune response to tumor antigen CP1 and its corre-
lation with improved survival in colon cancer patients.
Gastroenterology 2008, 134:998-1006.
226. Lee IN, Chen CH, Sheu JC, Lee HS, Huang GT, Yu CY, Lu FJ, Chow
LP: Identification of human hepatocellular carcinoma-related
biomarkers by two-dimensional difference gel electrophore-
sis and mass spectrometry.  J Proteome Res 2005, 4:2062-2069.
227. Evdokimova VN, Butterfield LH: Alpha-fetoprotein and other
tumour-associated antigens for immunotherapy of hepato-
cellular cancer.  Expert Opin Biol Ther 2008, 8:325-336.
228. Bracci L, Moschella F, Sestili P, La Sorsa V, Valentini M, Canini I, Bac-
carini S, Maccari S, Ramoni C, Belardelli F, Proietti E: Cyclophospha-
mide enhances the antitumor efficacy of adoptively
transferred immune cells through the induction of cytokine
expression, B-cell and T-cell homeostatic proliferation, and
specific tumor infiltration.  Clin Cancer Res 2007, 13:644-653.
229. Lotze MT, Line BR, Mathisen DJ, Rosenberg SA: The in vivo distri-
bution of autologous human and murine lymphoid cells
grown in T cell growth factor (TCGF): implications for the
adoptive immunotherapy of tumors.  J Immunol 1980,
125:1487-1493.
230. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S,
Linehan WM, Robertson CN, Lee RE, Rubin JT, et al.: A progress
report on the treatment of 157 patients with advanced can-
cer using lymphokine-activated killer cells and interleukin-2
or high-dose interleukin-2 alone.  N Engl J Med 1987,
316:889-897.
231. Osband ME, Lavin PT, Babayan RK, Graham S, Lamm DL, Parker B,
Sawczuk I, Ross S, Krane RJ: Effect of autolymphocyte therapy
on survival and quality of life in patients with metastatic
renal-cell carcinoma.  Lancet 1990, 335:994-998.
232. Onishi S, Saibara T, Fujikawa M, Sakaeda H, Matsuura Y, Matsunaga Y,
Yamamoto Y: Adoptive immunotherapy with lymphokine-
activated killer cells plus recombinant interleukin 2 in
patients with unresectable hepatocellular carcinoma.  Hepa-
tology 1989, 10:349-353.
233. Takayama T, Makuuchi M, Sekine T, Terui S, Shiraiwa H, Kosuge T,
Yamazaki S, Hasegawa H, Suzuki K, Yamagata M, et al.: Distribution
and therapeutic effect of intraarterially transferred tumor-
infiltrating lymphocytes in hepatic malignancies. A prelimi-
nary report.  Cancer 1991, 68:2391-2396.
234. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto
J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T: Adop-
tive immunotherapy to lower postsurgical recurrence rates
of hepatocellular carcinoma: a randomised trial.  Lancet 2000,
356:802-807.
235. Nakamori M, Iwahashi M, Nakamura M, Ueda K, Zhang X, Yamaue H:
Intensification of antitumor effect by T helper 1-dominant
adoptive immunogene therapy for advanced orthotopic
colon cancer.  Clin Cancer Res 2003, 9:2357-2365.
236. Curiel TJ: Tregs and rethinking cancer immunotherapy.  J Clin
Invest 2007, 117:1167-1174.
237. Rico M, Matar P, Zacarías Fluck M, Giordano R, Scharovsky O: Low
dose Cyclophosphmide (Cy) treatment induces a decrease
in the percentage of regulatory T cells in lymphoma-bearing
rats.  Proc Am Assoc Cancer Res 2007, 48:233.
238. Cheever MA, Greenberg PD, Fefer A, Gillis S: Augmentation of
the anti-tumor therapeutic efficacy of long-term cultured T
lymphocytes by in vivo administration of purified interleukin
2.  J Exp Med 1982, 155:968-980.
239. Ganss R, Ryschich E, Klar E, Arnold B, Hammerling GJ: Combina-
tion of T-cell therapy and trigger of inflammation induces
remodeling of the vasculature and tumor eradication.  Cancer
Res 2002, 62:1462-1470.
240. Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman
CN, Hodge JW: Irradiation of tumor cells up-regulates Fas and
enhances CTL lytic activity and CTL adoptive immuno-
therapy.  J Immunol 2003, 170:6338-6347.
241. Quezada SA, Peggs KS, Curran MA, Allison JP: CTLA4 blockade
and GM-CSF combination immunotherapy alters the intra-
tumor balance of effector and regulatory T cells.  J Clin Invest
2006, 116:1935-1945.Page 18 of 18
(page number not for citation purposes)
